

*A Joint Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), Australian Physiological Society (AuPS) and High Blood Pressure Research Council of Australia (HBPRCA)*

# ASCEPT AuPS HBPRCA JOINT MEETING

**ASCEPT-AuPS-HBPRCA**  
4 – 7 DECEMBER 2011

**HBPRCA**  
8 – 9 DECEMBER 2011  
PERTH CONVENTION AND EXHIBITION CENTRE



[www.ascept.org](http://www.ascept.org) • [www.aups.org.au](http://www.aups.org.au) • [www.hbprca.com.au](http://www.hbprca.com.au)

# ASCEPT AuPS HBPRCA JOINT MEETING

## WELCOME

On behalf of the Joint Program Committee and Society Councils we welcome you to the ASCEPT-AuPS-HBPRCA Joint Scientific Meeting in Perth from 4 – 9 December, 2011. The Joint Meeting program features the ASCEPT-AuPS meeting from Sunday 4 December to Wednesday 7 December with HBPRCA joining the meeting on Wednesday 7 December. The HBPRCA meeting will take place on 8 and 9 December 2011.

We hope the combination of plenary lectures, symposia and workshops, oral presentations and posters will be academically and scientifically stimulating and lead to new collaborations and research opportunities. With such a diverse group of researchers attending, there will be plenty of opportunities to network across the three Societies. Annual awards and prizes will also be presented at this joint meeting.

We extend a very warm welcome to all our invited speakers together with plenary speakers Dr Roland Jones, British Pharmacological Society; Professor Haruaki Nakaya, Japanese Pharmacological Society; Professor Robert Balaban, National Heart Lung and Blood Institute, USA; Professor Mark Hargreaves, University of Melbourne and Professor Peter Rothwell, University of Oxford.

You can expect an inspiring learning experience from the program as well as having plenty of opportunities to see the latest equipment and services on display by companies exhibiting at this year's trade exhibition.

We look forward to welcoming you to Perth.

Kind regards,

Carl Kirkpatrick  
Chairperson, Joint  
Program Committee

David Le Couteur  
ASCEPT President

David Allen  
AuPS President

Jaye Chin-Dusting  
HBPRCA President

## SPONSORS & EXHIBITORS

ASCEPT-AuPS-HBPRCA Joint Scientific Meeting 2011 gratefully acknowledges the generous support of the following organisations:



## INVITED SPEAKERS

### PLENARY SPEAKER BRITISH PHARMACOLOGICAL SOCIETY



Roland S. G. Jones, University of Bath

Roland Jones is a neuropharmacologist whose focus is the communication between neurones in the brain, particularly how it relates to pathological conditions and the actions of therapeutic drugs. Roland's primary research approach is to use electrophysiological recording of neuronal activity, but have complemented this on occasions, with neurochemical and behavioural techniques. His research career can conveniently be divided into two entities. From 1975–1986, he primarily studied the role of monoamine and neuropeptides in synaptic transmission, in relationship to depression and the action of antidepressant drugs. Since the mid-80s his research focus has been on the role of excitatory and inhibitory amino acids in synaptic transmission and how disturbance in the balance between these may underlie epileptic activity. These studies have largely employed *in vitro* approaches. In 1986, Roland pioneered the development of an *in vitro* rat brain slice preparation combining hippocampus and entorhinal cortex (EC) to study epileptogenesis in the temporal lobe. This preparation is now used in many labs around the world.

### PLENARY SPEAKER JAPANESE PHARMACOLOGICAL SOCIETY



Naruaki Nakaya, Chiba University

Dr Haruaki Nakaya is Dean of the Graduate School of Medicine and Professor of Department of Pharmacology, Chiba University. He received his M.D. from Hokkaido University School of Medicine in 1974. After training as a cardiologist in a city hospital for several years, he became a pharmacologist at Hokkaido University School of Medicine. He conducted postdoctoral studies with Arnold Schwartz at the University of Cincinnati, College of Medicine in 1981–82. In 1992 he was appointed Professor of Pharmacology at Chiba University School of Medicine. Dr Nakaya's research focuses on the pathophysiological roles and pharmacological modulation of cardiac ion channels.

### RAND MEDAL LECTURER



Greg Dusting  
Eye Research Australia/  
University of Melbourne

Professor Greg Dusting is Executive Director Research at the *Centre for Eye Research Australia*, formerly Director of Tissue Engineering at the *O'Brien Institute*, a Principal Research Fellow of the NHMRC, as well as Professor of Surgery, Ophthalmology and Pharmacology in *The University of Melbourne*. He is also a Visiting Professor at the *National Heart Centre, SingHealth* in Singapore for his collaborations on translational research in cardiac regenerative medicine and surgery. He has built a distinguished international reputation in Cardiovascular Pharmacology over 30 years with more than 220 publications which have attracted over 5000 citations in the medical and scientific literature. He is Associate Editor of 3 international pharmacological journals, and was elected a *Fellow of the British Pharmacological Society* in 2005. He has assembled a talented team of scientific, medical and surgical researchers, and has expert collaborators with expertise in stem cell biology, pharmacology, molecular biology and drug discovery in the cardiovascular, neuroscience, and ophthalmology fields. His mentoring role as Director has resulted in six of his former graduate students and post-doctoral fellows in recent years being appointed to chairs of Pharmacology or Medicine in prestigious academies in Australia, USA and China. His current team has a record of achievement in using stem cells for tissue engineering underpinned by angiogenesis. He has been invited to the Scientific Advisory Boards of two companies seeded from new compounds patented in his laboratory, and was a collaborator on a START grant awarded to Novogen P/L in 2000, and Commercial Ready grants for the start-up company NeuProtect P/L. He is currently collaborator in a multi-million dollar international consortium with the CSIRO involved in developing novel technology of biomaterials for transplant and bionics technologies, including cardiac tissue engineering and the Australian bionic eye venture. In 2011 he was awarded the Rand Medal for lifetime achievement in Pharmacology, by the *Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists*.

### PLENARY SPEAKER



Annamaria de Luca  
University of Bari

Annamaria de Luca graduated cum laude in Pharmacy at the University of Bari in 1985. After the PhD in Applied Pharmacology, she has been Assistant Professor (1989–1991) and Associate Professor (2000–2005) at the Faculty of Pharmacy, University of Bari, where she currently is Full Professor of Pharmacology. The intense teaching activity over the years to either undergraduate (Pharmacy, Medicinal Chemistry, Biotechnology) and PhD students, including thesis mentorship, widely covered the entire pharmacology field. Her research interest is the pathophysiology and pharmacology of neuromuscular disorders. Main research topics are the pharmacology of skeletal muscle ion channels involved in excitability disorders and in alteration of mechano-transduction and the pre-clinical studies in animal models of muscular dystrophies for identification of drug-able targets and prediction of potential clinical efficacy of therapeutics. Methodological approaches include *in vivo* behavioural techniques, *ex vivo* electrophysiology and physiology, biochemistry and molecular biology and histology. She has extensive collaborations worldwide with both public and private institutions, and is member of various Advisory Boards and Scientific Committees, such as the International TREAT-NMD Advisory Committee for Therapeutics (TACT).

# ASCEPT AuPS HBPRCA JOINT MEETING

## INVITED SPEAKERS

### AUPS INVITED LECTURER



**Mark Hargreaves,**  
The University of Melbourne

Mark Hargreaves was appointed Professor in 2005 and Head of Physiology at The University of Melbourne, in 2009. Prior to that, he was Professor of Exercise Physiology at Deakin University 1996–2005. He received his BSc in Physiology from The University of Melbourne in 1982, an MA in Exercise Physiology from Ball State University (USA) in 1984, and his PhD in Physiology from The University of Melbourne in 1989. His research interests focus on the physiological and metabolic responses to acute and chronic exercise, with a focus on carbohydrate metabolism. He is currently a Reviewing Editor of *The Journal of Physiology*, a Consulting Editor of *Journal of Applied Physiology*, an Associate Editor of *Exercise and Sport Sciences Reviews* and serves on the editorial boards of *American Journal of Physiology (Endocrinology & Metabolism)*, *Medicine and Science in Sports and Exercise* and *International Journal of Sports Nutrition and Exercise Metabolism*. He received the inaugural AK McIntyre Prize from AuPS in 1994.

### HBPRCA RD WRIGHT INVITED LECTURER



**Peter Rothwell,** University of Oxford

Professor Rothwell is a neurologist and clinical epidemiologist with an interest in stroke. He was awarded an MRC Senior Clinical Fellowship 2000 and set up the Stroke Prevention Research Unit in Oxford, which now employs about 30 researchers and support staff. He was made Professor of Clinical Neurology at the University of Oxford in 2004 and a fellow of the Academy of Medical Sciences in 2008. He has published over 250 scientific papers and several books. His research interests include the causes and prevention of stroke, particularly after a TIA or minor stroke, the link between hypertension and stroke, and the non-vascular effects of aspirin. He has also published widely on the more general theme of how best to apply the results of clinical trials and other forms of research to clinical decisions about individual patients in routine practice.

## SYMPOSIA SPEAKERS



**David Adams**  
RMIT University

David Adams is currently Professor and Director of the Health Innovations Research Institute at RMIT University, Melbourne. He was previously Professor and Chair of Physiology at the University of Queensland, Head of Department of Physiology & Pharmacology (1998–2000), Head of the School of Biomedical Sciences (2000–07) and Professorial Research Fellow in the Queensland Brain Institute (2008–09). He is an ARC Australian Professorial Fellow (2010–14) and a Chief Investigator on an NHMRC Program Grant (2005–14) to identify novel pain therapeutics based on venom peptides (conotoxins) from cone snails. His research focuses on the function and modulation of membrane receptors and ion channels and, in particular, nicotinic acetylcholine receptors and voltage-gated calcium channels. David has published 145 refereed journal articles (90 as first or senior author) in leading international physiology, pharmacology and neuroscience journals and 15 book chapters. He is the past President of the Australian Physiological Society (AuPS; 2004–10), a former member of the National Committee for Biomedical Science, Australian Academy of Science (2005–09) and a member of three Editorial Boards of international scientific journals.



**David Allen**  
University of Sydney

David Allen is Professor of Physiology at the University of Sydney. He trained in Physiology and Medicine at University College London where he also undertook his PhD on the activation of cardiac muscle. As a post-doctoral fellow he joined John Blinks at the Mayo Clinic in Minnesota where they devised the first method for measuring intracellular calcium in the heart. On his return to University College as a Lecturer, then Reader, he undertook a series of studies of calcium regulation in the heart and, in particular, its modification by muscle length and ischaemia. In 1989 he moved to Sydney to take up a Chair of Physiology. His current research interests encompass pacemaker function, ischaemia and reperfusion of the heart, skeletal muscle fatigue and the damage pathways in muscular dystrophy. In 2006 he was made a Fellow of the Australian Academy of Science. He is currently the President of the Australian Physiological Society.



**Naohiko Anzai**  
Dokkyo Medical University

Professor at Dokkyo Medical University, School of Medicine, Tochigi, JAPAN.

1994–1990: Medical studies at Chiba University, Japan

1990–1994: Resident at Chiba University Hospital

1995–1999: Assistant Professor at Kitasato University, Japan

1999–2001: Fellow at the Institute Molecular and Cellular Pharmacology (IPMC), CNRS, France

2001–2011: Assistant and associate professor at the Kyorin University.

2011–Present: Professor at Dokkyo Medical University, Tochigi, Japan

Activities: American Physiological Society, American Society of Nephrology, International Society of Nephrology, European Renal Association, Japanese Pharmacological Society, Physiological Society of Japan.



**Laura Bennet**  
The University of Auckland

Professor Laura Bennet is co-director of the Foetal Physiology and Neuroscience Group in the Department of Physiology, at the University of Auckland. She is a foetal systems physiologist with

a particular interest in cerebrovascular and neurophysiology and the physiological and pathological responses of the preterm foetus to hypoxia and infection. In addition to ongoing work on neuroprotection treatments and identifying biomarkers for predicting the at risk brain, she has recently begun to evaluate strategies for neurorepair. This work is targeted at developing treatments for cerebral palsy.



**James Brock**  
The University of Melbourne

James Brock is an NHMRC Senior Research Fellow in the Department of Anatomy and Cell Biology at the University of Melbourne. His primary research focus is the mechanisms of transmission at

sympathetic neurovascular junctions. Recently this work has focused on the effects of nerve injuries on blood vessel function. James also has a particular interest in the mechanisms that control the excitability of unmyelinated sensory nerve terminals. He developed a technique that for the first time has allowed electrical activity to be recorded directly from nociceptive nerve terminals. Using this approach he is investigating mechanisms that regulate action potential generation in nociceptors.



**Stefan Broer**  
Australian National University

Stefan Broer studied Biochemistry at the University of Tübingen, Germany from 1981 to 1986 and received his PhD in 1991. After being a research fellow of the German Science Foundation at the

University of Illinois in Chicago he was appointed as Junior Lecturer at the University of Tübingen in the Institute of Physiological Chemistry in 1993. In 2000 Stefan moved to the ANU as a Senior Lecturer in the School of Biochemistry and Molecular Biology. He was promoted to Associate Professor in 2006 and to full Professor in 2008. Stefan was treasurer and council member of the Australian Physiological Society from 2005–2009.



**Bradley Broughton**  
Monash University

Brad Broughton obtained his Ph.D. in 2005 at Deakin University before moving to the University of New Mexico in the United States where he was an American Heart Foundation Postdoctoral

Fellow. In 2008, Brad returned to Australia as a National Heart Foundation Postdoctoral Fellow and joined the Vascular Biology and Immunopharmacology Group in the Department of Pharmacology at Monash University. The focus of his current research is to examine G protein-coupled estrogen receptor signalling in the brain following stroke, use stem cells to treat stroke-induced injury, and to identify novel PET imaging agents that detect apoptosis in the brain post-stroke.



**Roger Byard**  
The University of Adelaide

Professor Roger Byard is the Marks Professor of Pathology at The University of Adelaide and a Senior Specialist Forensic Pathologist at Forensic Science SA in Adelaide, Australia. He has published

over 500 papers and book chapters dealing with topics in forensic and paediatric pathology, including issues related to herbal medicines. He has also authored a text on Sudden Death in the Young and edited an Encyclopaedia of Forensic and Legal Medicine. He is the Editor-in Chief of the international journal Forensic Science Medicine and Pathology.



**Russ Chess-Williams**  
Bond University

Russ Chess-Williams is Professor of Pharmacology and Head of Biomedical Science at Bond University. He has previously directed research and taught at the Universities of Sheffield, Liverpool and Cardiff

in the UK. His research interests centre on the development of new drug treatments for diseases of the lower urinary tract. He has published more than 400 articles and received funding from both British and Australian research councils. In recent years he has made a major contribution to the field of bladder function, particularly the many functions of the urothelium that are necessary for the maintenance of normal urinary continence.



**Ric Day**  
University of NSW

Richard Day is Professor of Clinical Pharmacology, UNSW and St Vincent's Hospital and is a Clinical Pharmacologist and Rheumatologist. He is former President of the DIA, an international organization

dedicated to the enhancement of the development of needed medicines world-wide. He heads the Masters in Drug Development at UNSW. His research includes the pharmacotherapy of gout, diabetes and psychotic disease and methods of achieving the safer use of medicines.

# ASCEPT AuPS HBPRCA JOINT MEETING



**Lea Delbridge**  
University of Melbourne

Professor Lea Delbridge heads the Cardiac Phenomics Laboratory in the Department of Physiology at the University of Melbourne. Her research focus is to understand structural and functional cardiopathology in different forms of hypertrophic cardiomyopathy associated with hormonal disturbances. Lea is World Council Member and President of the Australasian Section Council of the International Society of Heart Research (ISHR), a Council member for the Australian Physiological Society (AuPS), an elected Fellow of the Cardiac Society of Australia & NZ and appointed to the CSANZ Scientific Committee. She is also an editorial board member for a number of international journals, including *J Molecular & Cellular Cardiology*, *American Journal Physiology (Heart)*, and of course *CEPPI*!



**Anuwat Dinodum**  
University of Sydney

Anuwat Dinodum received his PhD from The University of Sydney in 1994. He was a Medical Foundation Research Fellow from 1994–1996, an NH&MRC RD Wright recipient from 2000–2003, and NH&MRC Senior Research Fellow from 2004–2010, all working in the Laboratory of Exocrine Physiology & Biophysics within the Sydney Medical School. His research focuses on identifying the cellular signalling mechanisms that regulate the epithelial Na<sup>+</sup> channel (ENaC). His research team was the first to discover the role of intracellular Na<sup>+</sup> and anions in the regulation of ENaC and showed that the G protein-coupled receptor kinase (GRK2) regulates activity of the channel.



**Igor R. Efimov**  
Washington University in St. Louis

Professor Igor Efimov is the Lucy and Stanley Lopata Distinguished Professor of Biomedical Engineering, Professor of Cell Biology and Physiology, Professor of Medicine and Professor of Radiology, Washington University in Saint Louis, Missouri. He received his MSc in 1986 and PhD in 1992 from Moscow Institute of Physics and Technology, Moscow Russia. Between 1992–1994, he was the Postdoctoral Research Associate at the University of Pittsburgh, USA. His faculty appointments include the Cleveland Clinic (1994–2000), Case Western Reserve University, Cleveland OH (2000–2004), and Washington University in St. Louis (2004–present), MO, USA. In 2009, Efimov founded Cardialen, Inc. which develops low energy defibrillation therapy for cardiac arrhythmias.



**Roger Evans**  
Monash University

Roger completed his PhD in pharmacology at Monash University in 1988. After post-doctoral positions at the Baker Institute and the University of Melbourne, he moved to the Department of Physiology at Monash University to take up an NHMRC RD Wright Fellowship (1997–2000) and then an NHMRC Senior Research Fellowship (2001–2010). In 2011 he moved to an academic position. Roger's main research interest is renal physiology. He teaches integrative cardiovascular physiology to 2nd and 3rd year BSc students and 1st and 2nd year MBBS students, and research skills to honours students. Roger is Co-Editor-in-Chief of *Clinical and Experimental Pharmacology and Physiology* and has authored more than 160 publications.



**Aleksandra Filipovska**  
The University of Western Australia

Aleksandra received her PhD in 2002 from the University of Otago, New Zealand. From 2003–2005 she was a NZ Foundation for Research, Science and Technology Fellow at the MRC Mitochondrial Biology Unit in Cambridge, the United Kingdom. In 2006 she relocated to Australia as a NHMRC Howard Florey Fellow and established her research group at the Western Australian Institute for Medical Research in Perth. She is currently an Australian Research Council Future Fellow and a group leader at the University of Western Australia. Her research interests are in mitochondrial gene expression and in targeting molecules with biological function to mitochondria and cells.



**Julia Gorelik**  
Imperial College London

Dr Julia Gorelik is a Reader within the National Heart and Lung Institute, Imperial College London. She works with Scanning Ion Conductance Microscopy (SICM), which enables recording of high-resolution topography of living cells and tissues. Dr Gorelik improved SICM to measure localisation of ion channels and receptors, contraction, rhythm and calcium dynamics of cardiomyocytes, allowing the study of arrhythmias and heart failure conditions on cultured heart cells and tissues. Recently she developed a combination of SICM and fluorescence resonance energy transfer techniques to investigate spatial 2-adrenoceptor-cyclic AMP signalling in failing and non-failing hearts (Science, 2010). She received Wellcome Trust University Award and Rector Research Excellence Award, 2010.



**Danny Green**  
University of Western Australia

Danny Green is a Winthrop Professor in the School of Sports Science, Exercise and Health at The University of Western Australia and the Chair of Cardiovascular Physiology in the Research Institute for Sport and Exercise Sciences at Liverpool John Moores University. His research investigates the reasons why exercise, exercise training and physical activity prevent heart disease and the best combinations of exercise and other preventative measures to minimise the risk of future development and re-occurrence of cardiovascular disease. His research encompasses the lifespan; from exercise training in prevention of the development of atherosclerosis in obese children and adolescents, to the management of patients with hypercholesterolemia, diabetes, coronary disease and heart failure. He has published over 150 peer reviewed articles in cardiology and physiology journals, delivered 20 invited keynote presentations at national and international conferences, been awarded 20 conference prizes and held continuous competitive grant funding since the 1990's. He has supervised 20 higher degree students at UWA and in the UK. In the 1990's, he established a research intensive Clinical Exercise Physiology service in the Cardiac Transplant Unit at Royal Perth Hospital (RPH), the first of its type in Australia. He is a currently an editor for *Experimental Physiology* and an editorial advisor for *Clinical Science (London)*.



**Rebecca Haddock**  
Australian National University

I completed a BSc at the UoW and then Hons/ PhD with Prof Hill (JCSMR, ANU) examining the mechanisms underlying vasomotion in small blood vessels. I then undertook a postdoctoral position

with Dr Cunnane (Uni. Of Oxford, UK) using confocal imaging to examine vascular smooth muscle calcium transients associated with peripheral nerve activity before joining Prof Morris and Dr Sandow (UNSW) as a NHMRC Doherty Fellow investigating the effects of diet-induced obesity on the vascular endothelium. Most recently, I have returned to the ANU where my studies have focussed on the effects of obesity on sympathetic activity in the resistance vasculature.



**Peter Henry**  
The University of Western Australia

Peter Henry is a graduate of UWA, completing a PhD in Pharmacology. Following a post-doctoral period at the University of Melbourne, he returned to UWA. He was awarded an NHMRC RD Wright Fellowship

for New Investigators, and then appointed to the NHMRC Fellowships Scheme as a Research Fellow. In 2001, Peter was appointed to an academic teaching and research position within the Pharmacology at UWA. He has spent over 20 years investigating novel pathways that protect the lungs from the injurious effects of airborne allergens, respiratory tract viruses, bacterial products and environmental toxins. These studies have typically involved collaborations with scientists from international pharmaceutical companies and academic institutions, and have been extensively funded by the NHMRC.



**Adam Hill**  
Victor Chang Cardiac Research Institute

I am a group leader in the Mark Cowley Lidwill research program in cardiac electrophysiology at the Victor Chang Cardiac Research Institute in Sydney. My research interests are split between

two related disciplines, ion channel physiology and computational cardiology. The main focuses of our work are: 1) Using novel approaches such as voltage clamp fluorometry and  $\gamma$ -value analysis to interrogate structure function relationships in ion channels and 2) Developing computational simulations of cardiac electrical activity to investigate the genesis of rhythm disturbances in cardiac tissue.



**Michael A. Hill**  
University of Missouri

Ph.D., University of Melbourne (1988). Postdoctoral training at Texas A&M University before holding academic positions in physiology at Eastern Virginia Medical School, RMIT University and University

of New South Wales. He is currently the Associate Director at the Dalton Cardiovascular Research Centre and Professor of Physiology, Department of Medical Pharmacology and Physiology, University of Missouri; and a Distinguished Research Fellow at RMIT University. Hill is also the President-elect Microcirculatory Society (USA) and Chair of Nominating Committee/Member of the Steering Committee, American Physiological Society (CV Section). He is also a member of the editorial boards for Microcirculation, Journal of Vascular Research and Frontiers in Vascular Physiology.



**Sarah Hilmer**  
University of Sydney

Sarah Hilmer (BScMed (Hons), MBBS (Hons), FRACP, PhD) is Associate Professor of Medicine at Sydney Medical School, University of Sydney; and Head of Department of Clinical Pharmacology and Staff

Specialist in Aged Care at the Royal North Shore Hospital in Sydney, Australia. She leads a program of research in geriatric pharmacology. Her basic research investigates hepatic drug disposition and toxicity in old age. Her clinical research measures medication exposure in older people and its association with geriatric syndromes. Her research and clinical work encompass education of medical students and junior medical officers on prescribing and quality use of medicines.



**Hikaru Hashitani**  
Nagoya City University

Hikaru Hashitani graduated in Medicine from Kyushu University, Japan in 1991, and then served as a urology residency at Kyushu University Hospital. He completed his PhD under the

supervision of Prof. Hikaru Suzuki at Nagoya City University, Japan in 1997. He undertook postdoctoral research with Prof. David Hirst at the Department of Zoology, Melbourne University from 1997–1999. After being appointed Research Associate in the Department of Physiology, Nagoya City University in 1999, he went to the Department of Pharmacology, University of Oxford to collaborate with Prof. Alison Brading from 2000–2003. He was appointed Lecturer in 2003 at the Department of Cell Physiology, Nagoya City University, then moved up to Professor and Head in 2010. His research interests have primarily focused on the mechanisms of spontaneous activity of smooth muscle in the urinary tract and male genital organs.



**Yvonne Hodgson**  
Monash University

Dr Yvonne Hodgson is the Manager of Academic programs and Quality for the School of Biomedical Science and a Senior Lecturer in the Department of Physiology. She has taught Physiology for 15 years

and has a special interest in respiratory physiology and practical class teaching. Yvonne is a coordinator for the AuPS Special Interest Group in Education. In 2010, Yvonne was the recipient of a Monash University Learning and Teaching Fellowship which she used to study the integration of peer learning with case based learning in a multidiscipline unit.



**Nicholas HG Holford**  
University of Auckland

Dr Holford is Professor of Clinical Pharmacology at the University of Auckland. His research interests include population PKPD analyses of clinical trials of drugs, PKPD in neonates and children and rational

approaches to dose individualization. He is currently developing the use of disease progress models for understanding clinical pharmacology with an emphasis on the effects of drugs in Parkinson's disease and predicting clinical outcome events through the use of biomarker driven hazard functions. A clinical trial testing the usefulness of an antibiotic dose calculator for neonates and infants is underway.

# ASCEPT AuPS HBPRCA JOINT MEETING



**Livia Hool**  
The University of Western Australia

Livia Hool completed her PhD at Royal North Shore Hospital, Sydney in 1995. She then undertook two years of postdoctoral research as a recipient of an American Heart Association

Postdoctoral Fellowship in the School of Medicine at Case Western Reserve University, Ohio. In 1998, she was awarded a Peter Doherty Fellowship from NHMRC and relocated to The University of Western Australia where she established the Cardiovascular Electrophysiology Laboratory. She is currently recipient of an ARC Future Fellowship and Honorary NHMRC Senior Research Fellowship. Her research interests include the study of the regulation of cardiac ion channels by hypoxia and oxidative stress, in particular the L-type Ca<sup>2+</sup> channel including redox modification of the channel protein.



**Rae-Chi Huang**  
The University of Western Australia

Dr R Huang graduated with a Bachelor of Medicine and Surgery from the University of Western Australia in 1995 and went on to gain further qualifications in Child and Public Health leading

to the completion of her PhD in 2010 titled Childhood Precursors of Adult Cardiovascular Disease. Dr Huang has worked as a clinical doctor for 8 years and is currently employed as an Assistant Research Professor at the School of Paediatrics and Child Health Research at the University of Western Australia as well as a Locum Endocrinology Consultant at Princess Margaret Hospital's Obesity Service.

As a paediatrician with an interest in nutrition, Dr Huang has been concerned by the increasing prevalence of insulin resistance and type II diabetes in obese paediatric patients. This has prompted investigation and research into the pathogenesis of cardiovascular disease with a particular emphasis on the early origins of health and disease. In particular, Dr Huang is exploring the role of phenotypes and genotypes in the development of cardiovascular risk factors and in the developmental evolution of cardiovascular risk factors and the possible origins in in-utero and early childhood.



**Michael Joyner**  
Mayo Clinic

Michael J. Joyner, M.D., is the Caywood Professor of Anaesthesiology at Mayo Clinic where he was named Distinguished Investigator in 2010. His interests include: cardiovascular regulation in humans, the

physiology of world records, and autonomic regulation of blood glucose. His undergraduate (1981) and medicine (1987) degrees are from the University of Arizona with residency and research training at Mayo. He has held leadership positions at Mayo, in the extramural research community, and with leading journals. His lab has been funded by the NIH since 1993, and former fellows have established independent research programs at leading institutions throughout the world.



**Yue-kun Ju**  
University of Sydney

Dr. Yue-kun Ju is a senior research fellow of Muscle Cell Function Laboratory, University of Sydney. Dr. Ju received a Medical Degree and Master Degree of Medicine at The Fourth Military Medical University (FMMU), Xian, P.R China. In 1989, she came to Australia and studied the persistent sodium channels in cardiac myocytes with late Prof. Peter Gage and Dr. David Saint at John Curtin School of Medical Research. She received her PhD in Neuroscience at Australian National University in 1994. Dr. Ju joined Prof. David Allen's laboratory in 1996 and has since that time pursued her research on the calcium mechanisms that regulate cardiac pacemaker activity. She now is a council member of ISHR Australasian; AuPS and an international fellow of American Heart Association. Her current research interests include IP<sub>3</sub> Receptors, TRPC and store-operated Ca<sup>2+</sup> channels and their possible involvement in cardiac arrhythmia.



**Barbara Kemp-Harper**  
Monash University

Barb Kemp-Harper is a Senior Research Fellow in the Department of Pharmacology, Monash University. After completing her PhD in 1995 she was awarded a NHMRC CJ Martin fellowship and then a Foundation for High Blood Pressure Research Postdoctoral Fellowship. Barb's research aims to identify novel strategies for the prevention and treatment of vascular disease with a focus on the NO/cGMP signalling pathway. She is a leading expert in the field of nitroxyl (HNO) pharmacology and her work has attracted funding from the NHMRC and other national funding bodies. She has also served as a Guest Editor for Antioxidants & Redox Signalling and she is currently an ASCEPT Councillor.



**Bronwyn Kingwell**  
Baker IDI Heart and Diabetes Institute

Professor Bronwyn Kingwell is a NHMRC Principal Research Fellow, and at the Baker IDI Heart and Diabetes Institute in Melbourne is Executive Director, Science Policy, co-Head of the Metabolism and Obesity Division (6 laboratories) and also leads the Healthy Lifestyle Research Centre. She has Professorial appointments in the Department of Medicine and Department of Physiology at Monash University and is a Principal Research Fellow at the University of Melbourne. She received her PhD in physiology from the University of Melbourne in 1991. Her multi-disciplinary Metabolic and Vascular Physiology Laboratory works on discovery and translation of novel molecular mechanisms to clinical application with a focus in the following areas:

- Vascular function including mechanical and endothelium properties and their relationship to cardiovascular risk.
- Identification of novel predictors of unstable coronary heart disease
- The role of HDL cholesterol in modulation of glucose and fat metabolism

Professor Kingwell holds NHMRC Program and Project grants and is a lead investigator on two Clinical Research Excellence grants. She has published over 140 peer-reviewed manuscripts in top-ranked general and discipline specific journals.



**Nigel Laing**  
The University of Western Australia and  
the Western Australian Institute for  
Medical Research

PhD Edinburgh University 1979; post-doc Oslo 1980; University of Western Australia since 1981. From 1976–1987, I was a neuroembryologist researching motor neuron and muscle development. In 1987–1988, I retrained in human molecular genetics at Duke University. In Western Australia, I developed research and diagnostic molecular neurogenetics laboratories and have identified 15 human disease genes, including mutations in skeletal muscle  $\alpha$ -actin in congenital myopathies and in slow skeletal/  $\beta$ -cardiac myosin in “Laing” distal myopathy. My laboratory is currently engaged in further gene discovery, understanding the pathobiology of the diseases, developing effective therapies and translating results into clinical and population health practice.



**Derek Laver**  
University of Newcastle

I received my PhD at the University of NSW in 1984 and I now lead the Channel Biophysics group at the University of Newcastle. The theme to my research career has been the use of biophysical methods to study membrane transport and ion channel function. I use electrophysiological techniques to measure ion channel function. Channel function is analysed using Markov theory to unravel and identify the complex mechanisms that control ion channels within cells. My research focus is now the calcium release channels in cardiac muscle and the role they play in normal cardiac pacemaking, cardiac arrhythmia and sudden death.



**Chun Guang Li**  
RMIT University

Associate Professor Chun Guang Li is the Group Leader of Herbal Pharmacology and Toxicology at School of Health Sciences and Health Innovations Research Institute, RMIT University. His current research is focused on the development of novel therapeutic agents from natural products. He has published over 100 papers and is currently on the editorial boards of several international journals on complementary medicines and pharmacology. He is the Vice President of the Australian Chinese Association for Biomedical Sciences, and the Co-Chair/Vice Chairmen of the 1st and 3rd Australia-China Biomedical Research Conference.



**Joe Lynch**  
Queensland Brain Institute, University of  
Queensland

Joe Lynch completed a BSc in Physics at the University of Melbourne. He subsequently completed a MBiomedE and a PhD at the University of NSW. Following postdoctoral periods in Germany, France and the Garvan Institute of Medical Research, he moved to University of QLD in 1996 as a Senior Lecturer in the School of Biomedical Sciences. He was awarded an NHMRC Research Fellowship in 2004 (renewed in 2009) and relocated to the QBI in 2007. His major research interests concern the molecular structure and function of the glycine and GABA-A inhibitory neurotransmitter ion channels.



**Peter McFawn**  
University of Western Australia

I completed my PhD in 1997 at the University of Western Australia working on developmental changes in bronchial compliance and airway responsiveness using isolated bronchial segments. After working at Queen’s University in Canada for four years on quantitative bronchoscopy and calcium sensitisation of airway smooth muscle I returned to Perth in 2002 as an academic staff member at The University of Western Australia. My current research interests focus on the bronchodilator effects of deep inspiration (DI) where by taking in a deep breath causes bronchodilation in healthy people a response that fails or is impaired in both asthma and chronic obstructive disease. Fortunately we have a productive collaboration with clinical colleges at the Queen Elisabeth II Medical Centre allowing us to obtain human lung samples from patients who are undergoing lung resection to treat lung cancer. I am also an associate editor for the Canadian Journal of Physiology and Pharmacology.



**Andrew McLachlan**  
University of Sydney

Andrew McLachlan is a pharmacist, academic and researcher with experience in clinical and experimental pharmacology. Andrew is Professor of Pharmacy (Aged Care) in the Faculty of Pharmacy at the University of Sydney and the Centre for Education and Research on Ageing at Concord Hospital. His research interests centre on understanding the causes and consequences of variability in response to medicines and how this informs their quality use. Andrew chairs the Human Research Ethics Committee at Concord Hospital, serves as the inaugural Chair of Australia’s National Medicines Policy Committee and is a member of Pharmaceutical Subcommittee of the Advisory Committee on Prescription Medicines.



**John Miners**  
Flinders University School of Medicine

John Miners received his PhD from Victoria University of Wellington and DSc from Flinders University. He is currently Professor of Clinical Pharmacology at Flinders University and Head of Flinders Medical Science and Technology (the biomedical cluster of disciplines). His major research interests are: sources of interindividual variability in drug metabolism and pharmacokinetics (particularly drug-drug interactions and pharmacogenetics); in vitro – in vivo extrapolation of drug clearance and drug-drug interaction potential; and structure-function relationships of UDP-glucuronosyltransferases and cytochromes P450. He has published over 240 research papers and reviews and is an ISI highly cited author in the discipline of pharmacology. He is a member of the editorial boards of seven international journals, and is the current Secretary of the International Society for the Study of Xenobiotics and a member of the Executive Committee of IUPHAR.



**Peter Molenaar**  
Queensland University of Technology/  
University of Queensland

Peter Molenaar is head of the in vitro human heart laboratory (Prince Charles Hospital) and Molecular human heart pharmacology laboratory (Institute of Health and Biomedical Innovation, QUT). The laboratories have a long standing interest in investigations of G-protein coupled receptor- and in particular beta-adrenoceptor subtype signalling in human heart.

# ASCEPT AuPS HBPRCA JOINT MEETING



**Karen Moritz**  
University of Queensland

Associate Professor Karen Moritz is a NH&MRC Senior Research Fellow in the School of Biomedical Sciences at the University of Queensland. The aim of her work is to understand how prenatal perturbations contribute to an increased risk of developing cardiovascular, renal and metabolic disease in adulthood. Over the last 5–7 years, her research has focused on determining the pivotal role played by the kidney in the “developmental programming” of adult disease. Her research has shown a reduced nephron endowment is associated with hypertension and renal impairment in the adult following excess maternal glucocorticoid exposure, maternal low protein diet, placental insufficiency and most recently, prenatal alcohol exposure.



**Margaret Morris**  
University of New South Wales

Professor Margaret Morris (BSc PhD Monash) is chair and Head of Pharmacology, School of Medical Sciences, UNSW. Her current research addresses critical questions concerning the impact of adverse early life events and lifestyle factors on chronic disease risk. Prof Morris uses neuropharmacological approaches to explore underlying brain mechanisms in epilepsy, obesity, diabetes, and the link between obesity and hypertension. Current NHMRC funded research includes intergenerational transmission of obesity, the psychology of eating and NPY based approaches to treating epilepsy. Prof Morris is responsible for pharmacology teaching to science, optometry and medical students.



**Janna Morrison**  
University of South Australia, South  
Australian Cardiovascular Health Network  
Fellow

An accomplished researcher in the field of foetal development, Janna Morrison is Head of the Early Origins of Adult Health Research Group in the Sansom Institute for Health Research at the University of South Australia. Dr Morrison has been funded as a fellow by the Heart Foundation since 2004 and is currently a South Australian Cardiovascular Health Network Fellow. Her current research centres on how the foetal cardiovascular system responds to changes in nutrient supply before conception and during pregnancy. After completing her PhD at the University of British Columbia, Janna held postdoctoral positions at University of Toronto and the University of Adelaide before joining the Sansom Institute for Health Research in 2006. Among her numerous awards and achievements, Janna received a South Australian Tall Poppy Science Award (2006) in recognition of her work examining the link between low birth weight and heart disease in adulthood.



**Tim Moss**  
Monash Institute of Medical Research

Dr Tim Moss obtained his PhD in Medicine from Monash University in 1999. He subsequently worked in the School of Women’s and Infants’ Health at the University of Western Australia and returned to Monash in late 2007. His present appointment is as a Senior Research Fellow in The Ritchie Centre, Monash Institute of Medical Research. The Ritchie Centre is Australia’s premier centre for experimental perinatology.

Tim’s work is aimed at understanding how common antecedents of prematurity influence development and alter babies’ risk of disease. In particular, his research has demonstrated profound effects on fetal lung development of exposure to inflammation before birth. His experiments have demonstrated the mechanisms whereby babies can be protected from, or made more vulnerable to, respiratory disease. His current work is aimed at using this knowledge to develop ways of preventing lung disease.



**Timothy V Murphy**  
University of NSW

Dr Murphy completed his PhD in 1992 at the University of Melbourne, Australia. He has held Postdoctoral positions funded by the NH&MRC and the Wellcome Trust (UK) and was inaugural Senior Scientist at RMIT Drug Discovery Technologies (RDDT). In 2004, Dr Murphy was appointed Senior Lecturer in the Department of Physiology, University of New South Wales, where he is currently based. Dr Murphy’s studies primarily focus on the interaction between intra-luminal pressure and vascular smooth muscle function in small arteries. He is also interested in the effects of obesity and diabetes on the function of small arteries.



**Louise Naylor**  
The University of Western Australia

Dr Louise Naylor’s research focus is on cardiac and vascular adaptations to exercise training, and the application of this work to optimise clinical outcomes for “at risk” populations.

During her research career, she has worked across the spectrum of health and disease, from elite athletes to chronically ill individuals (for example, patients with advanced heart failure, obesity and adolescents with type 2 diabetes) to generate a multifaceted understanding of cardiac and vascular exercise physiology. She is also involved in basic scientific research to add further mechanistic insights into regulation of the cardiovascular system.



**Joseph A. Nicolazzo**  
Monash University

Joseph graduated with a PhD in Pharmaceutics in 2005 (Monash University) assessing the buccal mucosa as an alternative site for systemic drug delivery. He is currently a lecturer at Monash University, where his research focuses on carrier proteins facilitating organic cation transport across the blood-brain barrier (BBB), the impact of disease-related BBB changes on pharmacotherapy, and identifying the mechanisms responsible for aberrant  $\beta$ -amyloid efflux across the BBB in Alzheimer’s disease. Joseph is a member of the Australasian Pharmaceutical Science Association (APSA) and the International Brain Barriers Society, and is the current Editor of the APSA newsletter.



**Kathryn North**  
Children's Hospital at Westmead and  
University of Sydney

Professor Kathryn North is the Douglas Burrows Professor of Paediatrics, Faculty of Medicine, University of Sydney and Head of the Institute for

Neuroscience and Muscle Research based at The Children's Hospital at Westmead.

Professor North is trained as a paediatric physician, neurologist and clinical geneticist and in 1994, was awarded a doctorate from the University of Sydney for research into Neurogenetics. She completed a postdoctoral fellowship in the Harvard Genetics Program and returned to Australia in 1995 as the recipient of the Children's Hospital Research Career Development Award. In 2000, she received the Sunderland Award from the Australian Neuroscience Society and in 2008 was named the Sutherland Lecturer by the Human Genetics Society of Australasia. In 2011, Prof North was awarded the GSK Australia Award for Research Excellence in recognition of her body of work as a translational research scientist and her world-first discovery of a common genetic mutation that influences muscle function and performance.

Her laboratory research interests focus on the molecular basis of inherited muscle disorders – particularly the muscular dystrophies and congenital myopathies – as well as genes which influence normal skeletal muscle function and elite athletic performance. Her clinical research focuses on clinical trials of therapies for muscular dystrophy as well as the development of interventions for children with learning disabilities. Professor North also runs the Neurogenetics Clinical Service at the Children's Hospital which cares for 1800 patients and their families with a range of disorders including neuromuscular diseases such as muscular dystrophy and neurofibromatosis.



**Coen AC Ottenheijm**  
VU University Medical Centre

Since 2010, I've worked as the Assistant Professor at the Dept. of Physiology at the VU University Medical Centre (Amsterdam, the Netherlands). My research focuses on the role of nebulin, and of other

sarcomeric thin filament proteins, in the pathogenesis of muscle weakness in nemaline myopathy. This work, which is funded by the EU and the Dutch Foundation for Scientific Research, concerns research on unique muscle biopsies from genetically characterized patients, and on nebulin-based KO mouse models. It is my goal to contribute to a better understanding of the pathogenesis of muscle weakness in NM, and to help develop new treatment strategies.



**Salvatore Pepe**  
Murdoch Children's Research Institute

Dr Salvatore Pepe is based at the Murdoch Children's Research Institute at the Royal Children's Hospital, Melbourne. His research is centred on the molecular study of cardiac metabolism and contraction, focused

on mitochondrial function, oxidative metabolism, the regulation of adaptive processes including cardioprotection, and mitochondrial defects that contribute to the development and progression of heart failure. A large part of this research is translational to the clinical and surgical setting for age-related and congenital heart diseases.



**Gavin Pinniger**  
The University of Western Australia

After obtaining his PhD in Biomedical Science from the University of Wollongong (2002), Dr Pinniger was awarded a Travelling Research Fellowship from The Wellcome Trust to undertake a post-

doctoral appointment at the University of Bristol, UK. He is currently Assistant Professor in Physiology, School of Biomedical, Biomolecular and Chemical Sciences, UWA. Dr Pinniger's research focuses on the physiological evaluation of skeletal muscle function. He is currently investigating the contribution of inflammatory cytokines and reactive oxygen species to skeletal muscle weakness and the impact of clinically relevant antenatal exposures such as glucocorticoids, inflammation and oxidative stress on foetal diaphragm function.



**Philip Poronnik**  
RMIT University

Philip Poronnik is Professor and Head of Pharmaceutical Sciences at RMIT University and Acting Deputy Head of School Learning and Teaching. He was previously Professor in Physiology

at the School of Biomedical Sciences at UQ. He is an ALTC Associate Fellow and his main interest in science education is leadership in the reinvigoration of the tertiary science curriculum. This includes pedagogies for creativity and visual literacies as well as academic rigour in the enabling sciences. He has an adjunct Professorial appointment in the Centre for Educational Innovation and Technology at UQ, is a co-opted member of the National Committee for Biomedical Sciences of the Australian Academy of Science and the National Secretary for ANZAAS. He recently received an ALTC grant to form the Collaborative Universities Biomedical Education Network (CUBENET).



**Claire Roberts**  
University of Adelaide

Claire Roberts directs Placenta Research in the Robinson Institute, University of Adelaide Australia. Her research aims to elucidate the molecular mechanisms by which placental trophoblasts invade

the maternal endometrium and its vasculature to sequester maternal blood flow to the placenta that is critical for pregnancy success. She is well known for her research on the role of IGFs in placentation and has expertise in this process in a variety of species including mouse, guinea pig and human. She is developing screening tools to predict which couples are at risk for developing common and life-threatening complications of pregnancy in which defective placentation is a feature including preeclampsia, pre-term birth and foetal growth restriction.



**Richard Robson**  
Christchurch Clinical Studies Trust Ltd

A clinical pharmacologist and consultant physician in Nephrology, Richard is an Associate Professor of Medicine at the Christchurch School of Medicine. He has considerable expertise and extensive experience

spanning 30 years in Australia, New Zealand and the UK. In addition to his clinical duties at Christchurch Hospital Richard provides an important consultancy and advisory role in pharmaceutical regulatory matters. He was responsible for initiating the introduction of Good Clinical Practice Guidelines for New Zealand. Richard is actively involved in academic and scientific organisations and is committed to the maintenance of professional standards. He is currently the Chairman of NZ Medicines Advisory and Assessment Committee (MAAC), the Chairman of the Standing Committee on Therapeutic Trials (SCOTT) and is on the NZ Generic subcommittee. Richard is the author of many original publications in pharmaceutical and nephrology research and he has wide experience in conducting pharmacokinetic and pharmacodynamics studies.

# ASCEPT AuPS HBPRCA JOINT MEETING



**Fraser Russell**  
University of the Sunshine Coast

Fraser Russell graduated with a BSc. from Deakin University in 1986, prior to amalgamation, and 12 years after University accreditation. He completed a PhD in Cardiovascular Pharmacology at the University of Melbourne (1994), and followed this with post-doctoral appointments at the University of Cambridge, UK (1994–98), University of Otago, NZ (1998–2000), and the University of Queensland (2000–04). In 2005, Dr Russell accepted a Faculty position at Australia's newest regional University, the University of the Sunshine Coast. Dr Russell is Senior Lecturer in Biochemical Pharmacology, and is course coordinator for Biochemistry, and two courses in Pharmacology. He has been an active member of ASCEPT since 1987.



**Grigori Rychkov**  
The University of Adelaide

Grigori Rychkov obtained his Bachelor of Science (Physics) degree in Rostov-on-Don state University (Russia) in 1983. After graduating from University he moved to Research Institute of Experimental Biology in Yerevan (Armenia) to do PhD in the area of biophysics of ion channels. In 1994 Dr Rychkov immigrated to Australia and started a post-doctoral position with Prof Alan Bretag in University of South Australia investigating gating properties of skeletal muscle chloride channels. In 2002 he was awarded ARC Research Fellowship and in 2007 NHMRC Senior Research Fellowship. His Current research investigates the role store-operated Ca<sup>2+</sup> channels and transient receptor potential (TRP) cation channels in the functions of animal cells.



**Thea Shavlakadze**  
The University of Western Australia

Dr Thea Shavlakadze (TS) is currently a Visiting Research Fellow at Novartis in Boston, USA for one year, working on a project with David Glass, Global Head of the Muscle Research Unit. TS is also a Research Associate Professor in the School of Anatomy and Human Biology at the University of Western Australia (UWA) where she holds research grants and currently co-supervises 5 PhD students. TS graduated from the Tbilisi State University, in Georgia with a Postgraduate degree in Cell Biology (1998) and was awarded a PhD with Distinction from the UWA in 2005. Since 2007, TS has obtained \$1.4 million in research funding, including being CI on 4 NH&MRC grants, and has 25 publications since 2000. The research of TS has targeted factors controlling the growth and maintenance of skeletal muscle mass and potential therapies for muscle disorders with a focus on in vivo studies and tissue analyses. Major areas of research include the role of Insulin-like Growth Factor-1 (IGF-1) in regulating skeletal muscle mass, and analyses of signalling pathways and other factors involved in skeletal muscle wasting, especially the progressive age-related loss of muscle mass and function known as sarcopenia.



**Velandai Srikanth**  
Monash Medical Centre, Monash University

Associate Professor Srikanth leads the Stroke and Ageing Research Group at Monash University. He works clinically as a stroke physician. He is an NHMRC/NHF Career Development Fellow whose primary interests are in the study of cerebrovascular disease and dementia, particularly in the overlap between the two. One of his fields of research is in the effects and mechanisms underlying phenotypes of cerebral small vessel disease.



**Roger Summers**  
Monash Institute of Pharmaceutical Sciences, Monash University

Roger Summers is Professor of Molecular Pharmacology and Theme Leader, Drug Discovery Biology at the Monash Institute of Pharmaceutical Sciences, Fellow of the British Pharmacological Society and PhD honoris causa Stockholm University. His research interests include ligand-directed signalling bias whereby different ligands acting at the same receptor can activate a particular spectrum of signalling pathways and the role of receptor scaffolding protein complexes in GPCR function and is supported by the NHMRC and ARC. Recipient of the David Syme Research Prize; ASCEPT/BPS Visiting Lectureship; Kathleen & Lovat Fraser Award of the NHF; Swedish RC Tage Erlander Visiting Professorship; Toho University Visiting Professorship, ASCEPT Life membership and Michael Rand Medal.



**Shane Thomas**  
Centre for Vascular Research, University of New South Wales

Shane Thomas received a PhD in 1999 from the University of Sydney. He undertook post-doctoral studies at the Whitaker Cardiovascular Institute, Boston University as an NHMRC CJ Martin fellow and then moved to the Centre for Vascular Research, University of New South Wales where he established an independent research group as an NHMRC RD Wright Career Development Fellow. He is currently Group Leader of the 'Redox Cell Signalling Group' at the same centre and institution. A major research focus of his group is defining the reduction and oxidation (redox) reactions and cell signalling pathways underlying endothelial dysfunction during cardiovascular disease and the development of new treatments to combat such dysfunction.



**Peter Thorn**  
University of Queensland

I am an Associate Professor in the School of Biomedical Sciences at the University of Queensland. Previously I worked for 10 years as a lecturer and, in the end as a Reader, at Cambridge University in the Department of Pharmacology. My studies focus on the regulation of secretion in epithelial cells. Despite their physiological significance, in the functioning of the lungs and gastrointestinal system, we know remarkably little about the actual mechanisms of secretion in these cells.



**Owen Woodman**  
RMIT University

Owen Woodman has more than 30 years of experience in research into the function of the cardiovascular system and the adverse effects of disease, working at institutions including

Harvard University and the University of Melbourne before joining RMIT University in 2007. He is presently Professor of Cell Biology in the School of Medical Sciences, RMIT University, Deputy Head of School (Research) and Head of the Discipline of Cell Biology and Anatomy. He has a particular interest in the development of new drugs for the treatment of acute myocardial infarction and vascular disease, including diabetes-induced vascular pathologies. His work in conjunction with colleagues from the Howard Florey Institute and the School of Chemistry, University of Melbourne has formed the basis of the commercial development of cardioprotective drugs by the biotechnology company Neuprotect Pty Ltd.



**Graeme Zosky**  
The University of Western Australia

Dr Graeme Zosky is a Research Fellow and Head of the Lung Growth and Respiratory Environmental Health Group at the Telethon Institute for Child Health Research. He has an undergraduate degree

in Zoology (1999) and a PhD in Zoology/Physiology (2003) from the University of Western Australia. He has since completed a Masters in Biostatistics at the University of Sydney (2010). His research focuses on the role of early life exposures in the development of chronic lung disease in later life. He is also an international leader in the design and application of techniques for assessing lung mechanics in animal models.



**Sab Ventura**  
Monash University

Sab obtained his PhD at Monash University in 1992. He has held research positions at the Royal Melbourne Hospital, University of Melbourne, University College London and Monash University.

He was appointed as a Senior Lecturer at Monash University in 2004 and is now also the Functional Biology Group Leader at the Monash Institute of Pharmaceutical Sciences. Sab is the co-author of 60 publications and his current research investigates the pharmacology of the prostate gland with a view to identifying new drug targets for the treatment of prostate disease. Sab is the current National Treasurer of ASCEPT.



# ASCEPT AuPS HBPRCA JOINT MEETING

## ASCEPT-AuPS-HBPRCA JOINT MEETING PROGRAM 2011

### SUNDAY 4 DECEMBER

0830 – 1130 ASCEPT Council Meeting (Meeting Room 11)

1030 – 1230 Speciality Training Committee RACP (Meeting Room 10)

1230 onwards **Registration desk open (Northern Convention Foyer, Level 2)**


1230 – 1330 Specialty Training Committee Lunch – Members and Trainees (Meeting Room 10)

1330 – 1730 Trainee Postgraduate meeting (Meeting Room 10)

Meeting Room 1		Meeting Room 2		Meeting Room 3	
1330 – 1530	<b>ASCEPT careers workshop</b>	1330 – 1630	<b>ASCEPT education workshop</b>	1400 – 1700	<b>ASCEPT pharmacogenomics workshop</b>

1730 – 1830 Opening Ceremony and Welcome to Country (Meeting Rooms 1 and 2)

AuPS Lecturer – Annamaria de Luca, University of Bari, Pre-clinical studies in rare diseases: the challenge to speed up pharmacotherapy in Duchenne Muscular Dystrophy

1830 – 2030 **Welcome Reception – ASCEPT and AuPS (Pavilion 1)** Proudly Sponsored by 

1930 ASCEPT clinical trainee dinner

1930 AuPS student mixer

### MONDAY 5 DECEMBER

0730 **Registration desk open (Northern Convention Foyer, Level 2)**

0800 – 0900 ASCEPT Breakfast Poster Presentations: Cardiovascular/Drug Disposition/Inflammation/Respiratory/ Pharmacogenomics/ Toxicology (Pavilion 1)

0900 – 1000 BPS Plenary Lecturer – Roland Jones, Mechanism of Action of Antiepileptic Drugs: A Synaptic Balancing Act?, p222

Chair: David Le Couteur (Riverview Rooms 4 & 5)

1000 – 1030 **Morning Tea – Exhibition and Poster Presentations (Pavilion 1)**

Riverview Room 5		Riverview Room 4		Meeting Room 3	
<b>Clinical pharmacology trainees sessions</b>		<b>Regulation of intracellular calcium signalling in vascular tissue</b>		<b>Elucidating abnormalities in cardiac metabolism</b>	
Chair: Evan Begg & Matt Doogue		Chair: Simon Potocnik		Chairs: Livia Hool & Helena Viola	
1030 – 1045	<b>Dabigatran Etxilate Maintenance Dosing – Audit of Initial Experience</b> Paul Chin, Christchurch Hospital, p99	1030 – 1050	<b>Selective modulation of ion channel subunit expression to probe regional differences in vascular smooth muscle BKCa function</b> Michael A. Hill, University of Missouri, p2	1030 – 1055	<b>Myocardial Insulin Resistance, Metabolic Stress and Autophagy</b> Lea Delbridge, University of Melbourne, p10
1045 – 1100	<b>An Evaluation of Felodipine as a Potential Perpetrator of Pharmacokinetic Drug-Drug Interactions in Healthy Volunteers using a Drug Cocktail Approach</b> Ben Snyder, Flinders University/ Flinders Medical Centre, p111	1050 – 1105	<b>Effects of advanced glycation end-products (AGE) on Ca<sup>2+</sup> signalling in vascular endothelial cells and endothelium-dependent responses in rat arteries</b> Tim Murphy, University of New South Wales, p3	1055 – 1120	<b>Mitochondrial dysfunction in congenital heart disease</b> Salvatore Pepe, Murdoch Children's Research Institute, p11
1100 – 1115	<b>A Retrospective Pharmacokinetic Review of the Busulphan Monitoring Service at Christchurch Hospital</b> Pam Buffery, Christchurch Hospital/Canterbury District Health Board, p118	1105 – 1120	<b>The role of STIM1/Orai1 in mediating Ca<sup>2+</sup> entry in vascular smooth muscle cell contractions</b> Grigori Rychkov, University of Adelaide, p4	1120 – 1145	<b>Regulation of mitochondrial gene expression</b> Aleksandra Filipovska, University of Western Australia, p12
1115 – 1130	<b>Steady-State Dosage Prediction for Perhexilene Maleate using the Initial Metabolite to Parent Ratio</b> Arlene Taylor, The Queen Elizabeth Hospital, p60	1120 – 1135	<b>How do flavonols cause relaxation of vascular smooth muscle?</b> Owen Woodman, Royal Melbourne Institute of Technology, p5	1145 – 1210	<b>Venom of box jellyfish, C. fleckeri, causes vasoconstriction and induces an increase in cytoplasmic calcium in cardiomyocytes, the latter likely through poorly-selective cation channels</b> V. Sutorin, Monash University, p13

1130 – 1145	<b>Plasma Metformin in Metformin-associated Lactic Acidosis Cases</b> Janna Duong, University of New South Wales, p73	1135 – 1145	<b>Symposium Open Discussion and questions to the speakers</b>	1210 – 1235	<b>Cardiovascular and skeletal muscle responses in orchidectomized rats following short-term chronic formoterol administration</b> V. Zaitsev, University of Melbourne, p14
1145 – 1200	<b>Mechanism-based Population Modelling of Vildagliptin Effects on Dipeptidyl Pptidase IV, Glucagon-Like Puptide 1, Glucose and Type 2 Diabetes</b> Cornelia Landersdorfer, Monash University, p186	1145 – 1200	<b>Tmem16a-generated Ca<sup>2+</sup>-activated Cl<sup>-</sup> currents exhibit similar regulatory properties to those recorded in vascular myocytes</b> N. Leblanc, p6	1235 – 1300	<b>Perhexiline is concentrated in both human atria and ventricles: perioperative analysis</b> C.-R. Chong, University of South Australia, p15
1200 – 1215	<b>High Risk Prescribing and Incidence of Frailty among Community-Dwelling Older Adults</b> Danijela Gnidjic, Royal North Shore Hospital and University of Sydney, p58	1200 – 1215	<b>Signalling through endothelial connexin40 modulates the myogenic constriction of arteries and regulates blood pressure</b> D.J. Chaston, p7		
1215 – 1230	<b>Comparing Medicines and their Management among the Older-Aged Living Independantly in different types of Retirement Villages</b> Sheila Doggrell, Queensland University of Technology, p21	1215 – 1230	<b>Multiple spontaneously active Ca<sup>2+</sup> waveforms in Nkx2.5-GFP cardiac lineage cells show selective modulation by If channel blockade, endothelin I and elevation of intracellular cAMP</b> J.M. Haynes, p8		

**1230 – 1330 Lunch – Exhibition and Poster Presentations (Pavilion 1)**

Pharmacogenomics SIG meeting ( Meeting Room 1)

Drug Discovery SIG meeting (Meeting Room 2)

Gastrointestinal and Urogenital SIG (Meeting Room 3)

	<b>Riverview Room 5</b>		<b>Riverview Room 4</b>		<b>Meeting Room 3</b>
	<b>Complementary medicines; not so complementary after all</b>		<b>The role of inflammation in the development of respiratory related disorders</b>		<b>Cardiac arrhythmia mechanisms</b>
	Chairs: Ian Musgrave & Janet Collier		Chairs: Jane Pillow & Gavin Pinniger		Chairs: Yue-kun Ju & David Allen
1330 – 1355	<b>Benefits and Risks of Complementary Medicines</b> Chun Guang Li, Royal Melbourne Institute of Technology, p211	1330 – 1345	<b>Protease-activated receptors: mediating pro-inflammatory or anti-inflammatory effects within the airways?</b> Peter Henry, University of Western Australia, p47	1330 – 1405	<b>The structure and function of the human sinus node</b> Igor Efimov, Washington University in St Louis, p55
1355 – 1420	<b>Interactions with complementary medicines</b> Andrew McLachlan, University of Sydney, p35	1345 – 1400	<b>Stimulated breathing movements in isolated bronchi: the impact on airway narrowing</b> Peter McFawn, University of Western Australia, p48	1405 – 1425	<b>Simulation of TRiA<sub>D</sub> markers of arrhythmic risk in acquired long QT syndrome</b> Adam Hill, Victor Chang Cardiac Research Institute, p56
1420 – 1445	<b>The Forensic Implications of Herbal Medicines</b> Roger Byard, University of Adelaide, p208	1400 – 1415	<b>Alterations in lung structure can perpetuate inflammation leading to chronic respiratory disease</b> Graeme Zosky, University of Western Australia, p49	1425 – 1445	<b>SR calcium release channel mechanisms for cardiac arrhythmias and their drug based therapy</b> Derek Laver, University of Newcastle, p57
1445 – 1500	<b>Chaperone "Boosting " and Hydralazine Cytoprotection against Carbonyl Stress</b> Philip Burcham, University of Western Australia, p112	1415 – 1430	<b>Antenatal inflammation and postnatal respiratory disease</b> Timothy Moss, Monash Institute of Medical Research, p50	1445 – 1500	<b>Confocal tiling images of inositol 1,4,5-trisphosphate receptors in intact mouse sinoatrial node</b> Y.K. Ju, University of Sydney, p58
1500 – 1515	<b>An LC-MS/MS Assay for Quantification of Cyclizine and Norcyclizine in a Pharmacokinetic Study of Subcutaneous Cyclizine in Palliative Care Patients</b> Berit Jensen, University of Otago, p17	1430 – 1445	<b>Impact of antenatal inflammation on diaphragm muscle function in the preterm lamb</b> Gavin Pinniger, University of Western Australia, p5a	1500 – 1515	<b>Role of cardiac Na<sup>+</sup> channel blockers in inhibiting the cardiac calcium release channel</b> D. Mehra, University of Newcastle, p59
1515 – 1530	<b>Effect of the Neurotoxin Saxitoxin on Neurite Outgrowth in Model Neuronal Cells</b> Katie O'Neill, University of Adelaide, p148	1445 – 1500	<b>The effect of antenatal betamethasone exposure on diaphragm contractile function in young rat progeny</b> D.L. Demmer, University of Western Australia, p52		

# ASCEPT AuPS HBPRCA JOINT MEETING

	Riverview Room 5	Riverview Room 4	Meeting Room 3
		1500 – 1515 <b>Serum Amyloid A is a candidate mediator for altered macrophage polarisation in cigarette smoke-related disease</b> E.X. Lim, University of Melbourne, p53	
		1515 – 1530 <b>Protective role of Nox1 oxidase against influenza A virus-induced lung inflammation</b> S. Selemidis, Monash University, p54	
1530 – 1600	<b>Afternoon Tea – Exhibition and Poster Presentations (Pavilion 1)</b>		
	Riverview Room 5	Riverview Room 4	Meeting Room 3
	<b>ASCEPT young investigators symposia</b> Chair: Barbara Kemp-Harper	<b>AuPS free communications: Nervous System</b> Chairs: Robyn Murphy & Robert Patuzzi	
1600 – 1630	<b>Allosteric Interactions across native Adenosine – A3 Receptor Homodimers: Quantification using Single-cell Ligand Binding Kinetics</b> Lauren May, Monash University, p214	1600 – 1615 <b>Isoflurane anaesthesia impacts on mouse hearing thresholds</b> J.M.E. Cederholm, University of New South Wales, p60	
1630 – 1700	<b>Research to Optimise Antibiotic Dosing for ICU Process – Challenging and Rewarding!</b> Jason Roberts, The University of Queensland, p218	1615 – 1630 <b>The role of type II spiral ganglion neurons in the regulation of hearing sensitivity via the medial olivocochlear efferent pathway</b> K.E. Froud, University of New South Wales, p61	
1700 – 1730	<b>The Pharmacology of Free Fatty Acid Receptors</b> Nicola Smith, Victor Chang Cardiac Research Institute, p122	1630 – 1645 <b>Assessing motor and gait phenotypes in Nedd4 and Nedd4-2-heterozygous mice</b> D. Bongiorno, Royal Melbourne Institute of Technology, p62	
1730 – 1800	<b>Identifying The Role of T Cells in the Development of Hypertension</b> Antony Vinh, p116	1645 – 1700 <b>'AuPS free communications: Skeletal Muscle</b> <b>The effect of non-severe dorsal burn injury on the contractile properties of fast-twitch hind limb skeletal muscle of the mouse</b> A.J. Bakker, University of Western Australia, p63	
		1700 – 1715 <b>The effect of N-acetylcysteine (NAC) on contractile function and protein-thiol oxidation in skeletal muscles of mdx mice</b> E. Assan, University of Western Australia, p64	
		1715 – 1730 <b>The impact of high dose vitamin C supplementation on skeletal muscle of healthy humans</b> G.D. Wadley, Deakin University, p65	
		1730 – 1745 <b>A novel scorpion toxin activates cardiac RyR2 calcium release channels at fM concentrations</b> A.F. Dulhunty, Australia National University, p66	
		1745 – 1800 <b>Spatio-temporal morphology of calcium sparks recorded on intact amphibian skeletal muscle fibres</b> L. Csernoch, University of Debrecen, p67	
1800 – 1900	<b>Education SIG meeting (Meeting Room 1)</b>		

## TUESDAY 6 DECEMBER

0730	Registration desk open (Northern Convention Foyer, Level 2)		
0800 – 0900	ASCEPT Breakfast Poster Presentations: Clinical/Gastro Urogenital/Neuropharmacology/Education/Drug Discovery (Pavilion 1)		
0900 – 1000	AuPS Invited Lecturer – Mark Hargreaves, The University of Melbourne, Exercise and skeletal muscle carbohydrate metabolism during exercise: from MilkyWay™ to MEF2, p68 Chair: David Allen (Riverview Rooms 4 & 5)		
1000 – 1030	Morning Tea – Exhibition and Poster Presentations (Pavilion 1)		
	<b>Riverview Room 5</b>	<b>Riverview Room 4</b>	<b>Meeting Room 3</b>
	<b>Structure-function studies of drug targets and drug metabolising enzymes</b>	<b>Challenges in pharmacology and physiology education</b>	<b>Functional consequences of genetic muscle conditions</b>
	Chairs: David Adams & Roger Summers	Chair: Lynette Fernandes	Chairs: Livia Hool & Gina Ravenscroft
1030 – 1049	<b>Ligand-directed signalling – an unbiased view</b> Roger Summers, Monash University, p209	1030 – 1045 <b>Challenges and opportunities in integrative physiology education</b> R.G. Evans, Monash University, p70	1030 – 1050 <b>Sarcomeric proteins and disease</b> Nigel Laing, University of Western Australia, p77
1049 – 1108	<b>Integrated approaches to understanding the structure and function of drug metabolizing enzymes</b> John Miners, Flinders University, p12	1045 – 1100 <b>How should we teach cardiovascular physiology and what do we want students to learn?</b> Y.M. Hodgson, Monash University, p71	1050 – 1125 <b>Sarcomere Function in Nemaline Myopathy</b> Coen Ottenheijm, VU University Medical Centre, p78
1108 – 1126	<b>Location of an Ivermectin Binding Site at the Glycine Receptor Chloride Channel</b> Joe Lynch, University of Queensland, p194	1100 – 1115 <b>Challenges for teaching pharmacology in a regional university</b> F.D. Russell, University of the Sunshine Coast, p72	1125 – 1145 <b>A gene for speed: ACTN3, athletes, evolution and impact on human health</b> Kathryn North, University of Sydney, p79
1126 – 1145	<b>Block and G-Protein Coupled Receptor Modulation of N-Type (CaV2.2) Calcium Channels by Analgesic Conotoxins</b> David Adams, Royal Melbourne Institute of Technology, p107	1115 – 1130 <b>Ensuring that Australian medical graduates can prescribe safely and effectively</b> S.N. Hilmer, Royal North Shore Hospital and University of Sydney, p73	1145 – 1200 <b>Phosphorylation of tropomyosin – response to sarcomeric stress?</b> M. Kreissl, University of Sydney, p80
1145 – 1200	<b>Allosteric Modulation of <math>\beta_2</math> Adrenoceptors</b> Erica Leonar, University of New South Wales, p143	1130 – 1145 <b>Panel discussion</b>	1200 – 1215 <b>Effects of cholinesterase inhibitor therapy on the neuromuscular junction in a mouse model of anti-MuSK myasthenia gravis</b> W.D. Phillips, University of Sydney, p81
1200 – 1215	<b>The Use of in Silico Screening to Identify <math>\alpha_1</math> – Adrenoceptor Subtype specific Ligands Lacking Off-Target Affinity</b> Angela Finch, University of New South Wales, p167	1145 – 1200 <b>Summative Assesments: When is enough too much?</b> D.A. Saint, University of South Australia, p74	1215 – 1230 <b>The efficacy of antisense oligomer mediated exon skipping is enhanced by concurrent administration of prednisolone in the mdx mouse</b> G.J. Pinniger, University of Western Australia, p82
1215 – 1230	<b>2'MEO6MF Activates Extrasynaptic <math>\alpha 4\beta 3\delta</math> GABA<sub>A</sub> Receptor in a Bi-Phasic Manner: A Possible Tool For Differentiating Stoichiometric Arrangements of the Receptor</b> Mary Chebib, University of New South Wales, p50	1200 – 1215 <b>Embedding responsible conduct in learning and research into the Pharmacology curriculum</b> Lynette Fernandes, University of Western Australia, p75	
		1215 – 1230 <b>Virtual Laboratories as an Extension of Practical Training in Pharmacology</b> Matthew Cheesman, University of Queensland, p216	

# ASCEPT AuPS HBPRCA JOINT MEETING

## 1230 – 1400 Lunch – Exhibition and Poster Presentations (Pavilion 1)

Cardiovascular SIG meeting (Meeting Room 1)

Toxicology SIG meeting (Meeting Room 2)

1400 – 1500 ASCEPT Invited Lecture (RAND) – Gregory Dusting, The University of Melbourne, Adventures in Pharmacology: From prostaglandins to tissue engineering and a bionic eye, p221

Chair: David Le Couteur (Riverview Rooms 4 & 5)

## 1500 – 1530 Afternoon Tea – Exhibition and Poster Presentations (Pavilion 1)

	Riverview Room 5	Riverview Room 4	Meeting Room 3
	<b>ASCEPT student oral prize session</b>	<b>Abnormalities in ion transport and signaling in muscle ageing and disease</b>	<b>Epithelial transport – expanding the boundaries</b>
	Chair: Barbara Kemp-Harper	Chair: Livia Hool	Chair: Stefan Broer
1530 – 1545	<b>Establishment and characterization of an AT3B prostate cancer cell-induced rat model of bone cancer pain</b> Arjun Muralidharan, The University of Queensland, p32	1530 – 1555 <b>Ion channels as biomarkers and therapeutic targets in dystrophic myopathies</b> Annamaria de Luca, University of Bari, p83	1530 – 1545 <b>Regulation of serum uric acid levels by epithelial transporters</b> Naohiko Anzai, Dokkyo Medical University, p89
1545 – 1600	<b>Type-1 interferon signalling is a potential therapeutic target following Traumatic Brain Injury</b> Ila Karve, University of Melbourne, p84	1555 – 1612 <b>Early pathways to muscle damage in muscular dystrophy</b> David Allen, University of Sydney, p84	1545 – 1600 <b>Vesicle-associated membrane protein 8 (VAMP 8) is a SNARE selectively required for sequential granule-to-granule fusion</b> Peter Thorn, University of Queensland, p90
1600 – 1615	<b>Glucocorticoids retard breast tumour cell migration</b> Ebony Fietz, University of Melbourne, p136	1612 – 1629 <b>Exploring novel therapies for frailty and muscle disease</b> Paul Gregorevic, Baker IDI Heart and Diabetes Institute, p85	1600 – 1615 <b>Protein complexes – organising transport and function in space and time</b> Phil Poronnik, Royal Melbourne Institute of Technology, p91
1615 – 1630	<b>Old age, frailty and the population pharmacokinetics of gentamicin</b> Claire Johnston, University of Sydney, p163	1629 – 1645 <b>Targeting Sarcopenia: muscle innervation and exercise</b> Tea Shavlakadze, University of Western Australia, p86	1615 – 1630 <b>Regulation of the epithelial Na<sup>+</sup> channel (ENaC) by G protein-coupled receptor kinase, GRK2</b> Anuwat Dinudom, University of Sydney, p92
1630 – 1645	<b>Voriconazole pharmacokinetics and therapeutic drug monitoring: a multi-centre analysis</b> Michael Dolton, University of Sydney, p181	1645 – 1700 <b>Different capacity for store-dependent Ca<sup>2+</sup> influx and Ca<sup>2+</sup> extrusion across the plasma membrane of wild-type and dystrophic mdx mouse muscle</b> T.R. Cully, University of Queensland, p87	1630 – 1645 <b>Membrane complexes involved in protein digestion and nutrient signaling</b> Stefan Broer, Australia National University, p93
1645 – 1700	<b>The effect of ageing and diet on paracetamol hepatotoxicity in rats</b> Sarah Mitchell, University of Sydney, p187	1700 – 1715 <b>The effect of Phospholipase A2 inhibition on contractile function in normal and dystrophic skeletal muscle</b> J. Lam, University of Western Australia, p88	1645 – 1700 <b>The activity of epithelial sodium channel is negatively regulated by H-Ras via an ERK1/2 dependent pathway</b> I.H. Lee, University of Sydney, p94
1700 – 1715	<b>The lipid kinase PI3K – C2a important roles in platelet function in mice by regulating the avidity of the major platelet integrin <math>\alpha 11b/\beta 3</math></b> Jessica Mountford, Monash University, p147		1700 – 1715 <b>Structural basis for the functional differences between ASCT1 and EAATs</b> A.J. Scopelliti, University of Sydney, p95
1715 – 1730	<b>Identification and initial evaluation of a prototype clotting time test for enoxaparin</b> Abhishek Gulati, University of Otago, p224		1715 – 1730 <b>Effect of human amnion epithelial cells on stroke outcome in mice</b> K.W.E. Taylor, Monash University, p96
1730 – 1900	ASCEPT AGM (Riverview Room 5)		AuPS AGM (Meeting Room 3)
1900 – 2000	APTEN meeting (Meeting Room 11)		

## WEDNESDAY 7 DECEMBER

0730	Registration desk open (Northern Convention Foyer, Level 2)
0800 – 0900	Clinical Pharmacology SIG Meeting (Meeting Room 1)
0900 – 0930	JPS Plenary Lecturer – Haruaki Nakaya, Chiba University, Pharmacological Approaches to Atrial Fibrillation: Current Status and Future Perspective, p215 Chair: David Le Couteur, President ASCEPT (Riverview Rooms 4 & 5)
0930 – 1000	HBPRCA RD Wright Invited Lecturer – Peter Rothwell, John Radcliffe Hospital, Non Vascular Effects of Aspirin Chair: Jaye Chin-Dusting, President HBPRCA (Riverview Rooms 4 & 5)

### 1000 – 1030 Morning Tea – Exhibition and Poster Presentations (Pavilion 1)

	Riverview Room 5		Riverview Room 4		Meeting Room 3
	<b>Novel drug targets for UG disorders associated with ageing</b>		<b>Fundamental mechanisms of function of the normal and diseased heart</b>		<b>Exercise and cardiovascular function in health and disease</b>
	Chair: Betty Exintaris		Chairs: Lea Delbridge & Peter Molenaar		Chair: Michael McKenna
1030 – 1100	<b>Interstitial cells (pericytes) in the urothelium of the bladder that control the microvasculature</b> Hikaru Hashitani, Nagoya City University, p210	1030 – 1100	<b>Nanoscale SICM/FRET insights into <math>\beta</math>-adrenoceptor distribution and cAMP compartmentation in cardiac myocytes</b> Julia Gorelik, National Heart and Lung Institute, p98	1030 – 1055	<b>Skeletal muscle hyperemia during exercise: do we have all the answers now?</b> Michael Joyner, Mayo Clinic, p105
1100 – 1115	<b>Urothelial Causes of Bladder Overactivity and Directions for Drug Development</b> Russ Chess-Williams, Bond University, p168	1100 – 1115	<b>Evidence for altered communication between the L-type <math>Ca^{2+}</math> channel and mitochondria in a model of cardiomyopathy</b> Livia Hool, University of Western Australia, p99	1055 – 1120	<b>Exercise and cardiac adaptations</b> Louise Naylor, University of Western Australia, p106
1115 – 1130	<b>Acid – A novel sensory and motor stimulant in the urinary bladder?</b> Elizabeth Burcher, University of New South Wales, p201	1115 – 1130	<b>Mechanically induced arrhythmias in hypertrophic heart</b> David Saint, University of Adelaide, p100	1120 – 1145	<b>Exercise and vascular adaptation</b> Danny Green, University of Western Australia, p107
1130 – 1145	<b>What makes the <math>\alpha 1A</math>-adrenoceptor gene express the <math>\alpha 1L</math>-adrenoceptor functional phenotype?</b> Sab Ventura, Monash University, p129	1130 – 1145	<b>Molecular determinants and functional consequences of the <math>\beta 1L</math>-adrenoceptor in the heart</b> Peter Molenaar, Queensland University of Technology, p101	1145 – 1200	<b>Interaction of muscle glycogen availability and nutrition on cell signalling and myofibrillar protein synthesis following resistance exercise</b> D.M. Camera, Royal Melbourne Institute of Technology, p108
1145 – 1200	<b>Effect of Lipopolysaccharide from Escherichia Coli on Urothelial Stretch Induced ATP Release</b> Kylie Mansfield, University of Wollongong, p142	1145 – 1200	<b>Acute chemotherapeutic treatment causes hyperphosphorylation of cardiac ryanodine receptors</b> N.A. Beard, Australia National University, p102	1200 – 1215	<b>Effect of age on the dynamic response of muscle hyperaemia during exercise</b> S. Green, University of Otago, p109
1200 – 1215	<b>Non-Genomic Steroid Action in Stromal Cells derived from Human Prostate</b> Victoria Oliver, Monash University, p91	1200 – 1215	<b>Insulin regulated aminopeptidase/AT4 receptor deficiency is both cardio- and vaso-protective in angiotensin II-infused mice</b> T.A. Gaspari, Monash University, p103	1215 – 1230	<b>Exercise hypertension is related to aortic reservoir function: a first in-human exercise central haemodynamic study</b> M.G. Schultz, University of Tasmania, p110
1215 – 1230	<b>Role of hyperpolarization-activated cyclic nucleotide gated cation channels in pyloureteric peristalsis</b> R.J. Lang, Monash University, p97	1215 – 1230	<b>The cardiac actions of the nitroxyl (HNO) donor Angeli's salt are thiol-sensitive and cGMP-dependent: impact of diabetes</b> R.H. Ritchie, Baker IDI Heart and Diabetes Institute, p104		

# ASCEPT AuPS HBPRCA JOINT MEETING

## 1230 – 1400 Lunch and ASCEPT Poster Prize Session (Pavilion 1)

### Drug Disposition SIG Meeting (Meeting Room 1)

	Riverview Room 5		Riverview Room 4		Room 3
	<b>Clinical trials – commerce or science?</b>		<b>Free communications: joint cardiovascular</b>		<b>AuPS free communications: respiration and smooth muscle</b>
	Chair: Paul Rolan		Chair: Stephen Harrap		Chair: Trent Reardon & Peter McFawn
1400 – 1410	<b>COX-2 inhibitors: lessons?</b> Ric Day, University of New South Wales, p220	1400 – 1415	<b>Postural influences on the mechanical and neural components of the cardiac baroreflex</b> C.E. Taylor, University of Western Sydney, p111	1400 – 1415	<b>Decreased passive compliance of mesenteric and uterine arteries in pregnant relaxin deficient (Rln-/-) mice</b> J.H. Gooi, University of Melbourne, p115
1410 – 1420	<b>Early human studies – goals and directions</b> Richard Robson, Christchurch Clinical Studies Trust Ltd, p301	1415 – 1430	<b>Exposure to alcohol during fetal life causes persistent changes in vascular function and passive mechanical arterial wall properties in the offspring</b> M. Tare, Monash University, p112	1415 – 1430	<b>Perivascular sympathetic neuropathy in the streptozotocin type I diabetic rat model</b> N.J. Johansen, University of Melbourne, p116
1420 – 1430	<b>The design and analysis of clinical trials for Parkinson's disease</b> Nick Holford, University of Auckland, p7	1430 – 1445	<b>Chemokine receptors as novel pharmacological targets to reduce blood pressure during experimental hypertension in mice</b> C.T. Chan, Monash University, p113	1430 – 1445	<b>The effects of temperature on the biophysical properties of warm- and cold-adapted pulmonary surfactant</b> L.N.M. Suri, University of South Australia, p117
1430 – 1500	<b>Panel discussion</b>	1445 – 1500	<b>The valsartan intensified primary care reduction of blood pressure (VIPER-BP) study: a multicentre, randomized trial</b> S. Stewart, Baker IDI Heart and Diabetes Institute, p114	1445 – 1500	<b>Airway narrowing, smooth muscle force and wall compliance at low and high mechanical strains</b> T.K. Ansell, University of Western Australia, p118

## 1500 – 1530 Afternoon Tea – Exhibition and Poster Presentations (Pavilion 1)

	Riverview Room 5		Riverview Room 4		Room 3
	<b>Novel pharmacological strategies for neurological diseases</b>		<b>Being a small baby or being born preterm: which is worse is for your health?</b>		<b>Mechanisms underlying vascular dysfunction in disease and injury</b>
	Chairs: Alyson Miller & Bruno Meloni		Chairs: Lawrie Beilin & Trevor Mori		Chairs: Caryl Hill & Dirk van Helden
1530 – 1549	<b>Alterations in Blood Brain Barrier Function in Alzheimer's Disease and Implications for Drug Delivery</b> Joseph Nicolazzo, Monash University, p26	1530 – 1550	<b>Predicting Pregnancy Outcomes: Small or Early?</b> Claire Roberts, University of Adelaide, p119	1530 – 1551	<b>Novel Nitric Oxide Mimetics in the Treatment of Vascular Dysfunction</b> Barbara Kemp-Harper, Monash University, p125
1549 – 1608	<b>Is the Novel G Protein-Coupled Receptor a Sex Specific Target for Cerebrovascular Dysfunction and Stroke?</b> Bradley Broughton, Monash University, p165	1550 – 1610	<b>Do corticosteroids have different effects in preterm or small babies?</b> Karen Moritz, University of Queensland, p120	1551 – 1609	<b>Studies into the molecular mechanisms of oxidative stress-induced endothelial dysfunction and its prevention</b> Shane R. Thomas, University of New South Wales, p126
1608 – 1626	<b>Targeting NPY for the Development of Anti-Seizure Drugs</b> Margaret Morris, University of New South Wales, p162	1610 – 1630	<b>Pathways from being small or preterm to a vulnerable heart</b> Janna Morrison, University of South Australia, p121	1609 – 1627	<b>Diet-induced obesity alters sensory nerve activity in rat small mesenteric artery</b> Rebecca E. Haddock, Australia National University, p127

	Riverview Room 5		Riverview Room 4		Room 3
	<b>Novel pharmacological strategies for neurological diseases</b>		<b>Being a small baby or being born preterm: which is worse is for your health?</b>		<b>Mechanisms underlying vascular dysfunction in disease and injury</b>
	Chairs: Alyson Miller & Bruno Meloni		Chairs: Lawrie Beilin & Trevor Mori		Chairs: Caryl Hill & Dirk van Helden
1626 – 1645	<b>Novel Clinical Strategies for the Treatment of Small Cerebral Vessel Disease</b> Velandai Srikanth, Monash University, p223	1630 – 1650	<b>Preterm neonatal cardiovascular instability: understanding the fetus when evaluating the newborn</b> Laura Bennet, University of Auckland, p122	1627 – 1645	<b>Effects of spinal cord injury on neurovascular function</b> James A. Brock, University of Melbourne, p128
1645 – 1700	<b>Neuroimmunopharmacology of Opioids &amp; Alcohol: Behavioural Cellular Signaling &amp; Binding Evidence of a Role for Toll-Like Receptors</b> Mark Hutchinson, University of Adelaide, p49	1650 – 1710	<b>Cardiovascular and metabolic outcomes of offspring born small or early: the Raine Study</b> Rae-Chi Huang, University of Western Australia, p123	1645 – 1700	<b>Hydrogen peroxide increases responses to nerve, phenylephrine and potassium stimulation in mouse tail artery by multiple mechanisms</b> T.F. Reardon, University of Melbourne, p129
1700 – 1715	<b>In Vitro Maturation and Function of Catecholaminergic Neurons Derived from Mouse Embryonic Stem Cells: Implications for Transplantation</b> John Haynes, Monash University, p101	1710 – 1730	<b>The Role of Lifestyle Factors vs Early Origins of Cardiovascular Disease</b> Bronwyn Kingwell, Baker IDI Heart and Diabetes Institute, p124	1700 – 1715	<b>Cellular localisation of relaxin receptors in arteries and veins and region-dependent responses to in vivo relaxin administration in male rats</b> M. Jelinic, University of Melbourne, p130
1715 – 1730	<b>Type-1 Interferon Signalling is involved in the Regulation of Neuro-Inflammation in Alzheimer's Disease</b> Myles Minter, University of Melbourne, p66			1715 – 1730	<b>Inhaled and intravenous methacholine evoke differential effects on bronchial blood flow and 3rd generation airway dimensions in awake sheep</b> S.W. White, University of Newcastle, p131
1730 – 1800	<b>Closing Ceremony and awarding of prizes (Riverview Room 5)</b>				
1900 – 2330	<b>Conference Dinner (Bellevue Ballroom 2, Level 3, PCEC)</b>				
1900 – 1930	Pre-dinner Drinks and cocktails				
1930 – 2330	Dinner and Entertainment				

## AuPS POSTER PRESENTATIONS

PAVILION 1, LEVEL 1

### MONDAY 5 DECEMBER

Monday 5th December – Presenters of even numbered posters to be present at 12.30pm in Pavilion 1  
Tuesday 6th December – Presenters of odd numbered posters to be present at 12.30pm in Pavilion 1

Poster Board Number	Abstract Title	Presenter	Abstract Number	Session Name
1	Protein thiol oxidation is a possible mediator of muscle fatigue	I.G.J. Lim	16P	AuPS – Poster Presentation
2	The acute effects of curcumin exposure on skeletal muscle contractile function	M. Grzelak	17P	AuPS – Poster Presentation
3	The contractile properties of slow and fast skeletal muscles from protease activated receptor-1 null mice	K. Sitparan	18P	AuPS – Poster Presentation
4	Changes in oxidative stress decrease the rate of protein synthesis in cultured C2C12 myotubes	Y. Chang	19P	AuPS – Poster Presentation
5	Phosphorylation of small heat shock proteins in response to heat stress	N.T. Larkins	20P	AuPS – Poster Presentation
6	Muscle-specific HSP72 over-expression improves muscle structure and function in mdx dystrophic mice	S.M. Gehrig	21P	AuPS – Poster Presentation
7	A protocol for the routine generation of engineered muscle tissue from the C2C12 cell line	J.M. Peters	22P	AuPS – Poster Presentation
8	Unexpected redundancy between $\beta$ -adrenoceptor subtypes in early muscle regeneration	J.E. Church	23P	AuPS – Poster Presentation
9	Quantification of endogenous and maximal sarcoplasmic reticulum calcium content in human / vastus lateralis/ muscle	C.R. Lamboley	24P	AuPS – Poster Presentation
10	Intramuscular administration of formoterol attenuates loss of muscle mass and function after denervation of the rat masseter muscle	C. van der Poel	25P	AuPS – Poster Presentation
11	The effects of the chemo-protective agent 3H-1,2-dithiole-thione (D3T) on dystrophic pathology in an animal model of Duchenne muscular dystrophy	T. Kennedy	26P	AuPS – Poster Presentation
12	Citrulline prevents fasting-induced muscle cell atrophy /in vitro/	R. Koopman	27P	AuPS – Poster Presentation
13	Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia	K.T. Murphy	28P	AuPS – Poster Presentation
14	Effects of carnosine on sarcoplasmic reticulum $Ca^{2+}$ -handling and contractile properties in human /vastus lateralis/muscle fibres	T.L. Dutka	29P	AuPS – Poster Presentation
16	Elevated intra-cardiac angiotensin II modulates myocardial autophagic signalling induced by insulin resistance	K.M. Mellor	31P	AuPS – Poster Presentation
17	Regulation of RyRs by intracellular $Ca^{2+}$ and $Mg^{2+}$ compared in sheep, rat and human heart	K. Walweel	32P	AuPS – Poster Presentation
18	Studying the effects of hypoxia on mitochondrial metabolism in human heart using a genome-wide metabolic network model	L.M. Edwards	33P	AuPS – Poster Presentation
19	The effects of intra-uterine growth restriction on metabolic organ growth, cardiomyocyte $Ca^{2+}$ -handling properties, and contractile function in juvenile rats	T.J. Harvey	34P	AuPS – Poster Presentation
20	Acute Intralipid infusion may improve left ventricular function /via/increases in circulating ketones	N.G. Lawler	35P	AuPS – Poster Presentation
21	The L-type $Ca^{2+}$ channel agonist BayK8644 selectively augments the $\alpha_1A$ -adrenoceptor-mediated component of nerve-evoked contraction in rat tail artery	H.S. Al Dera	36P	AuPS – Poster Presentation
22	Decreased passive compliance in the uterine arteries of late pregnant relaxin gene knockout mice is exacerbated by ageing	M. Richardson	37P	AuPS – Poster Presentation
23	Lymphatic pump failure and valve dysfunction in response to modest gravitational loads: a contributing mechanism to peripheral lymphedema	J.P. Scallan	38P	AuPS – Poster Presentation
24	Brain IL-6- and PG-dependent actions of IL-1 $\beta$ and lipopolysaccharide in avian fever	M. Marais	39P	AuPS – Poster Presentation
25	Midgestation intrafetal cortisol infusion in sheep increases lung surfactant protein mRNA, but not to the same degree as the normal parturition surge in cortisol	S. Orgeig	40P	AuPS – Poster Presentation
26	Antecedent exercise attenuates the glycaemia-increasing effect of a 30-second sprint	T.D. Justice	41P	AuPS – Poster Presentation
27	Platelet-derived growth factor (PDGF) regulates Epithelial $Na^{+}$ channels /via/ERK1/2	S.H. Song	42P	AuPS – Poster Presentation
28	Exploring cysteine transport by the human glutamate transporter, EAAT3	R. Bashour	43P	AuPS – Poster Presentation
29	A simple technique for monitoring changes in nasal resistance using acoustic input resistance	A.M. Cook	44P	AuPS – Poster Presentation
30	Rotation of the eyes (not the head) potentiates the sound-evoked post-auricular muscle response	R.B. Patuzzi	45P	AuPS – Poster Presentation
31	A simple and reliable method for testing transgene zygosity using quantitative real-time PCR	S.K. Morton	46P	AuPS – Poster Presentation

### MONDAY 5 DECEMBER

Poster Board Number	Abstract Title	Presenter	Abstract Number	Session Name
1	NON-CHRONOTROPIC COMPONENT CHANGES IN PARASYMPATHETIC HEART RATE VARIABILITY: A SENSITIVE MARKER FOR PERCEIVED EXAMINATION STRESS IN HEALTHY UNIVERSITY STUDENTS	Slade Matthews	6	Cardiovascular
2	ENDOTHELIN-1 AND CALCITONIN GENE-RELATED PEPTIDE PHARMACOLOGY IN HUMAN AND RAT REGIONAL VASCULAR BEDS	Richard Hughes	34	Cardiovascular
3	ARE CIRCULATING ADULT STEM CELLS INCREASED IN ACUTE DECOMPENSATED HEART FAILURE?	Rohit Samuel	57	Cardiovascular
4	ALTERED TRPV3 EXPRESSION AND FUNCTION IN RAT UTERINE RADIAL ARTERIES DURING PREGNANCY	Arjna Kanagarajah	63	Cardiovascular
5	SYMPATHETIC INHIBITION BY CLONIDINE AND ROLE OF ENDOGENOUS NORADRENALINE IN CARDIAC AND VASCULAR TISSUES OF THE RAT AND MOUSE	Pravin Rajasekaran	64	Cardiovascular
6	T-TYPE CALCIUM CHANNEL INVOLVEMENT IN VASCULAR TONE IS REDUCED BY NITRIC OXIDE	Lauren Howitt	81	Cardiovascular
7	VASORELAXANT EFFECT OF PROPOLIS FROM AUSTRALIAN STINGLESS BEES (T. CARBONARIA) ON ISOLATED PORCINE CORONARY ARTERY	Flavia Carmelina Massaro	87	Cardiovascular
8	SIGNALING PATHWAYS ASSOCIATED WITH ADENOSINE RECEPTOR MEDIATED CORONARY VASODILATION IN THE RAT HEART	Roselyn Rose'Meyer	88	Cardiovascular
9	ANGIOTENSIN II-INDUCED ACTIVATION OF HYPERTROPHIC SIGNALLING IN CARDIOMYOCYTES: INVOLVEMENT OF EPIDERMAL GROWTH FACTOR RECEPTORS	Zhen Wang	93	Cardiovascular
10	MULTIPLE SPONTANEOUSLY ACTIVE Ca <sup>2+</sup> WAVEFORMS IN NKX2.5-GFP CARDIAC LINEAGE CELLS SHOW SELECTIVE MODULATION BY IF CHANNEL BLOCKADE, ENDOTHELIN I AND ELEVATION OF INTRACELLULAR CAMP	John Haynes	100	Cardiovascular
11	THE EFFECTS OF VANILLOID-LIKE AGENTS ON PLATELET AGGREGATION	Dominic Geraghty	104	Cardiovascular
12	TRPC3 CHANNEL ROLE IN ENDOTHELIUM-DEPENDENT RELAXATION IN RAT MESENTERIC ARTERY	Sevvandi Senadheera	106	Cardiovascular
13	TASTE RECEPTORS ARE DIFFERENTIALLY EXPRESSED IN CARDIAC CELL TYPES AND DISPLAY DISTINCT TEMPORAL EXPRESSION PATTERNS IN RAT HEART	Simon Foster	110	Cardiovascular
14	COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF UROCORTIN 1, 2 AND 3 IN HEALTHY SHEEP	Kashyap Patel	127	Cardiovascular
15	HYPOTENSION IN THE ACUTE STAGES OF TAKO-TSUBO CARDIOMYOPATHY: PATHOPHYSIOLOGICAL CORRELATES	Cher-Rin Chong	132	Cardiovascular
16	EFFECT OF HUMAN AMNION EPITHELIAL CELLS ON STROKE OUTCOME IN MICE	Kimberly Taylor	135	Cardiovascular
17	INSULIN REGULATED AMINOPEPTIDASE (IRAP/AT4R) INHIBITION PREVENTS ATHERO-SCLEROSIS AND IMPROVES PLAQUE STABILITY	Tracey Gaspari	138	Cardiovascular
18	HETEROMERISATION WITH THE BRADYKININ TYPE 2 RECEPTOR ALTERS ARRESTIN RECRUITMENT AND INTERNALISATION OF THE ANGIOTENSIN II TYPE 2 RECEPTOR	Elizabeth Johnstone	139	Cardiovascular
19	CHEMOKINE RECEPTORS AS NOVEL PHARMACOLOGICAL TARGETS TO REDUCE BLOOD PRESSURE DURING EXPERIMENTAL HYPERTENSION IN MICE	Christopher Chan	140	Cardiovascular
20	ALDOSTERONE CAUSES CEREBRAL VASCULAR OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION: ROLE OF THE MINERALOCORTICOID RECEPTOR	Quynh Nhu Dinh	144	Cardiovascular
21	"GENETIC PHARMACOLOGY": A NOVEL METHOD FOR EXAMINING THE FUNCTION OF PROTEINS OF INTEREST UNCOVERS A ROLE FOR THE LIPID KINASE PI3K-C2 $\alpha$ IN PLATELET FUNCTION IN VIVO	Justin Hamilton	146	Cardiovascular
22	EFFECTS OF TANSHINONE IIA ON DOXORUBICIN-INDUCED CARDIAC TOXICITY	Guohui Cai	152	Cardiovascular
23	CIRCUMVENTING NITRIC OXIDE (NO) RESISTANCE IN PLATELETS FROM HYPERCHOLESTEROLEMIC MICE WITH THE NO-INDEPENDENT GUANYLYL CYCLASE STIMULATORS ISOPROPYLLAMINE NONOate (IPA/NO) AND BAY 41-2272	Michelle Bullen	153	Cardiovascular
24	TOCOTRIENOL AND TOCOPHEROL IMPROVE ENDOTHELIUM DEPENDENT RELAXATION IN RAT AORTA IN THE PRESENCE OF SUPEROXIDE	Saher Ali	155	Cardiovascular
25	THE ROLE OF CASPASE-1 ACTIVATION IN ANGIOTENSIN II-INDUCED HYPERTENSION	Shalini Murali Krishnan	172	Cardiovascular
26	MECHANISMS CONTRIBUTING TO THE HYDROGEN SULFIDE INDUCED VASORELAXATION OF MIDDLE CEREBRAL ARTERIES IN THE RAT	Eloise Streeter	176	Cardiovascular
27	ALPHA-ADRENOCEPTOR ANTAGONISM BY CRASSOSTREA GIGAS OYSTER EXTRACT INHIBITS NORADRENALINE-INDUCED VASCULAR CONTRACTION IN HEALTHY RATS	Kylie Connolly	184	Cardiovascular
28	INVOLVEMENT OF THE CCR2-CCL8 AXIS IN LEUKOCYTE INFUX INTO THE VASCULAR WALL DURING EXPERIMENTAL HYPERTENSION IN MICE	Jeffrey P Moore	203	Cardiovascular
29	UPTAKE AND STORAGE OF SERUM LIPIDS BY VASCULAR SMOOTH MUSCLE CELLS INVOLVES MACROPINOCYTOSIS AND DOWNREGULATION OF ATP-BINDING CASSETTE TRANSPORTER A1	Jennifer Rivera	212	Cardiovascular
29b	ENDOTHELIUM-DERIVED NITROXYL-MEDIATED RELAXATION IS RESISTANT TO SUPEROXIDE SCAVENGING AND PRESERVED IN DIABETIC RAT AORTA	Chen Huei Leo	37	Cardiovascular
44	PREDICTION OF DOCETAXEL CLEARANCE AND THE KETOCONAZOLE-DOCETAXEL INTERACTION	Matthew Doogue	4	Drug Disposition
45	DEVELOPMENT OF A HIGHLY SENSITIVE UPLC-MS BASED APPROACH TO THE ASSESSMENT OF UDP-GLUCURONIC ACID UPTAKE BY HUMAN LIVER SMOOTH ENDOPLASMIC RETICULUM	Andrew Rowland	11	Drug Disposition
46	DEVELOPMENT OF A MODEL FOR FUNCTIONAL STUDIES OF ABCG2 EFFLUX EMPLOYING A 'NON-MODIFIED' BEWO CLONE (B24)	Andrew Crowe	13	Drug Disposition
47	IMAGING THE IN VIVO ZONAL DISPOSITION OF INDOCYANINE GREEN IN RAT LIVER BY CONFOCAL MICROSCOPY	Peng Li	22	Drug Disposition
48	USING IMAGING TECHNIQUES TO STUDY PERCUTANEOUS TRANSPORT	Qian Zhang	27	Drug Disposition
49	REGULATION OF UDP-GLUCURONOSYLTRANSFERASE (UGT) 2B15 AND 2B17 BY ANDROGENS AND ESTROGENS IN PROSTATE CANCER CELLS	Dong Gui Hu	28	Drug Disposition

## ASCEPT POSTER PRESENTATIONS

### MONDAY 5 DECEMBER

Poster Board Number	Abstract Title	Presenter	Abstract Number	Session Name
50	THE EFFECTS OF N-TERMINAL DOMAIN AMINO ACID SUBSTITUTIONS ON UDP-GLUCURONOSYLTRANSFERASE 1A9 (UGT1A9) ACTIVITY	Porntipa Korprasertthaworn	29	Drug Disposition
51	THE INHIBITORY EFFECTS OF UREMIC TOXINS ON DRUG METABOLISING ENZYME ACTIVITY IN VITRO	Kyra Barnes	36	Drug Disposition
52	APPLICATION OF PROTEIN HOMOLOGY MODELLING TO IDENTIFY CRITICAL RESIDUES INVOLVED IN THE BINDING OF COFACTOR TO UDP-GLUCURONOSYLTRANSFERASE 2B7 (UGT2B7)	Nuy Chau	38	Drug Disposition
53	TRANSPORT OF COLISTIN ACROSS THE BLOOD-BRAIN BARRIER DURING SYSTEMIC INFLAMMATION AND BACTERIAL INFECTION	Liang Jin	44	Drug Disposition
54	INVESTIGATION INTO THE EXPRESSION OF THE UDP GLYCOSYLTRANSFERASE 3A1 AND 3A2 GENES AND THE REGULATORY ROLE OF THE TRANSCRIPTION FACTOR GATA-4	Alex Haines	46	Drug Disposition
55	POPULATION PHARMACOKINETICS OF ARTEMETHER, LUMEFANTRINE AND THEIR RESPECTIVE METABOLITES IN PAPUA NEW GUINEAN CHILDREN WITH UNCOMPLICATED MALARIA	Sam Salman	96	Drug Disposition
56	SYNERGY OF ANTIMICROBIAL COMBINATIONS CHARACTERIZED BY A NOVEL EXPERIMENTAL AND MECHANISM-BASED MODELLING APPROACH	Cornelia Landersdorfer	174	Drug Disposition
57	RELATIONSHIP BETWEEN BLOOD AND KIDNEY CONCENTRATIONS OF THE IMMUNOSUPPRESSANT TACROLIMUS IN RENAL TRANSPLANT RECIPIENTS	Benedetta Sallustio	178	Drug Disposition
58	DOUBLE BETA-LACTAM COMBINATIONS CAN ERADICATE NON-REPLICATING PERSISTERS (NRPs) AND PREVENT RESISTANCE OF PSEUDOMONAS AERUGINOSA (PA) VIA UNIQUE PENICILLIN-BINDING PROTEIN (PBP) OCCUPANCY PATTERNS	Jurgen Bulitta	180	Drug Disposition
59	AGE-RELATED PSEUDOCAPILLARISATION OF THE LIVER SINUSOID IMPAIRS THE HEPATIC CLEARANCE OF DIAZEPAM	Sarah Mitchell	188	Drug Disposition
60	MECHANISM-BASED MODELLING OVER THREE EXPERIMENTAL TIERS TO EVALUATE AND OPTIMIZE THE SYNERGY OF COLISTIN (COL) AND RIFAMPICIN (RIF) AGAINST ACINETOBACTER BAUMANNII (AB)	Jurgen Bulitta	196	Drug Disposition
81	METFORMIN INDUCES UNCOUPLING PROTEIN 2 IN MURINE MACROPHAGES	David A Joyce	47	Inflammation/ Respiratory
82	ROSIGLITAZONE OVERCOMES RESISTANCE TO $\beta$ 2-ADRENOCEPTOR AGONISTS IN SMALL AIRWAYS IN MOUSE LUNG SLICES	Chantal Donovan	75	Inflammation/ Respiratory
83	FLOW CYTOMETRIC ANALYSIS OF TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 (TRPV1) IN HUMAN LEUKOCYTE POPULATIONS	Dominic Geraghty	77	Inflammation/ Respiratory
84	THE ANTIMICROBIAL PEPTIDE LL-37 INHIBITS MIGRATION OF THE PROSTATE CANCER PC-3 CELL LINE	Yan Tu	109	Inflammation/ Respiratory
85	PAR2 RECEPTOR COUPLING TO TRPV4 IS DEPENDENT ON TYROSINE PHOSPHORYLATION	Fe Abogadie	120	Inflammation/ Respiratory
86	ANNEXIN-1 AND FORMYL PEPTIDE RECEPTORS IN BREAST TUMOUR CELL PROLIFERATION	Jay Rautela	133	Inflammation/ Respiratory
87	GLUCOCORTICOID RETARD BREAST TUMOUR CELL MIGRATION	Ebony Fietz	136	Inflammation/ Respiratory
88	TNF $\alpha$ , IL-4 AND IL-13 IMPAIR GLUCOCORTICOID ACTION IN HUMAN BRONCHIAL EPITHELIAL CELLS	Christine Keenan	137	Inflammation/ Respiratory
89	MECHANISMS CONTRIBUTING TO PROSTATE CANCER SIZE IN MICE: NOX2 OXIDASE AND T LYMPHOCYTES	Ian Harrison	145	Inflammation/ Respiratory
90	MECHANISM OF COX-2 INHIBITION BY SAIKOSAPONIN-D	Yiguang Lin	205	Inflammation/ Respiratory
112	EFFECT OF CYP2B6 GENETIC VARIABILITY ON PHARMACOKINETICS AND METABOLISM OF KETAMINE AS A COANALGESIC IN CHRONIC CANCER PAIN PATIENTS: A PILOT STUDY	Yibai Li	51	Pharmacogenomics
113	CATION TRANSPORTERS IN DIABETIC PATIENTS TREATED WITH METFORMIN	Shaun Kumar	69	Pharmacogenomics
114	PHARMACOGENOMIC TESTING FOR 193 PATIENTS PRESCRIBED PARACETAMOL/CODEINE (30MG) FOLLOWING LAPAROSCOPY	Leslie Sheffield	157	Pharmacogenomics
115	EFFECT OF IL4 RECEPTOR $\alpha$ -CHAIN POLYMORPHISMS ON STAT6 ACTIVATION AND PLASMA LEVELS OF IgE IN MALAYSIAN ASTHMATICS	Vijaya Raj	189	Pharmacogenomics
116	INTERACTING PHARMACOGENETIC DETERMINANTS OF METHADONE RESPONSE: ABCB1 AND OPRM1	Daniel Barratt	207	Pharmacogenomics
122	INHIBITION OF CYSTATHIONINE-GAMMA-LYASE AND THE BIOSYNTHESIS OF ENDOGENOUS HYDROGEN SULPHIDE AMEROLIATES GENTAMICIN-INDUCED NEPHROTOXICITY	Robert Kinobe	16	Toxicology
123	MAD MAGGOTS – FORENSIC INVESTIGATIONS OF A PSYCHOTROPIC DRUG IN A RAT BRAIN MODEL	Sarah Bushby	43	Toxicology
124	OXYPURINOL, ALLOPURINOL AND ALLOPURINOL-1-RIBOSIDE IN PLASMA FOLLOWING AN ACUTE OVERDOSE OF ALLOPURINOL IN A PATIENT WITH ADVANCED CHRONIC KIDNEY DISEASE	Diluk Kannangara	72	Toxicology
125	A RAPID UPLC-MS METHOD FOR THE QUANTIFICATION OF 4-CHLORO-2-METHYLPHENOXYACETIC ACID (MCPA) IN PLASMA AND DIALYSIS EFFLUENT	Shane Spencer	76	Toxicology
126	COMBATING OXIDATIVE STRESS: THE LINK BETWEEN HEAT SHOCK PROTEIN-90 AND HYDRALAZINE CYTOPROTECTION	Lauren Sharp	108	Toxicology

# ASCEPT POSTER PRESENTATIONS

## MONDAY 5 DECEMBER

Poster Board Number	Abstract Title	Presenter	Abstract Number	Session Name
127	TUMOUR NECROSIS FACTOR- $\alpha$ RENDERS MACROPHAGES RESISTANT TO A RANGE OF CANCER CHEMOTHERAPEUTIC AGENTS THROUGH NF- $\kappa$ B-MEDIATED ANTAGONISM OF APOPTOSIS SIGNALLING	Susan Lo	113	Toxicology
128	AN EVALUATION OF ACETAMINOPHEN PROTEIN ADDUCTS IN MALAYSIAN PATIENTS WITH ACETAMINOPHEN OVERDOSE	Zamri Chik	114	Toxicology
129	MOLECULAR TOXINOLOGY OF LESSER KNOWN VENOMOUS AUSTRALIAN SNAKES – DEMANSIA VESTIGIATA AND DEMANSIA PSAMMOPHIS	Daryl Yang	124	Toxicology
130	CROSS-NEUTRALISATION OF PUFF ADDER AND TIGER SNAKE VENOM BY CSL POLYVALENT AND SAIMR POLYVALENT ANTIVENOMS RESPECTIVELY	Nicki Konstantakopoulos	141	Toxicology
131	TOXICITY ACCOMPANYING PRIOR ACROLEIN EXPOSURE OF A549 LUNG CELL MONOLAYERS AT THE AIR-LIQUID INTERFACE IS BLOCKED BY HYDRALAZINE	Melissa Soh	151	Toxicology
132	THE EFFECT OF AGEING ON PHARMACOKINETICS AND NRF2-MEDIATED PROTECTION IN PARACETAMOL INDUCED HEPATOTOXICITY OF FISHER 344 RATS	John Mach	170	Toxicology
133	THE EFFECT OF AGEING AND DIET ON PARACETAMOL HEPATOTOXICITY IN RATS	Sarah Mitchell	187	Toxicology
134	XENOBIOTIC METABOLISM IN AUSTRALIAN MARSUPIALS: A MOLECULAR PERSPECTIVE	Suong Ngo	192	Toxicology
135	XENOBIOTIC DETOXIFICATION IN AUSTRALIAN MARSUPIALS: AN OVERVIEW	Suong Ngo	193	Toxicology

## TUESDAY 6 DECEMBER

Poster Board Number	Abstract Title	Presenter	Abstract Number	Session Name
30	EFFECTS OF ADULT AGE ON PREDICTED TOTAL DRUG CLEARANCE	Matthew Doogue	5	Clinical
31	96-HOUR LEVOBUPIVACAINE INFILTRATION FOR POST-OPERATIVE PAIN MANAGEMENT – A PROTEIN BINDING ISSUE	Ray Morris	15	Clinical
32	THIAMINE IN ALCOHOL DEPENDENCE	Ellen Rees	56	Clinical
33	POLYPHARMACY AND ADVERSE OUTCOMES: DETERMINING THE BEST CUT-OFF FOR POLYPHARMACY ASSOCIATED WITH GERIATRIC SYNDROMES, FUNCTIONAL STATUS AND MORTALITY IN OLDER ADULTS	Danijela Gnjidic	59	Clinical
34	A POPULATION PHARMACOKINETIC (POPPK) MODEL FOR METFORMIN OVER A BROAD RANGE OF RENAL FUNCTION	Shaun Kumar	68	Clinical
35	INVESTIGATING THE FRACTIONAL RENAL CLEARANCE OF URATE (FCU) AS A RISK FACTOR FOR GOUT	Sheena Ramasamy	70	Clinical
36	PHARMACOKINETICS OF METFORMIN IN PATIENTS WITH TYPE 2 DIABETES	Janna Duong	71	Clinical
37	SUCCESSFUL USE OF ALLOPURINOL IN A PATIENT ON DIALYSIS	Diluk Kannangara	74	Clinical
38	IMPROVING VANCOMYCIN PRESCRIBING AND MONITORING: A QUALITY IMPROVEMENT INTERVENTION	Cameron Phillips	82	Clinical
39	OFF-LABEL USE OF RECOMBINANT FACTOR VII IN TWO TERTIARY HOSPITALS IN QUEENSLAND	Peter Donovan	123	Clinical
40	OLD AGE, FRAILITY AND THE POPULATION PHARMACOKINETICS OF GENTAMICIN	Claire Johnston	163	Clinical
41	CLINICAL UTILITY OF POSACONAZOLE THERAPEUTIC DRUG MONITORING	Michael Dolton	182	Clinical
42	TRIALS OF WITHDRAWAL OF MEDICATIONS IN HEART FAILURE – A SYSTEMATIC REVIEW AND META-ANALYSIS	Ingrid Hopper	204	Clinical
43	IDENTIFICATION AND INITIAL EVALUATION OF A PROTOTYPE CLOTTING TIME TEST FOR ENOXAPARIN	Abhishek Gulati	224	Clinical
61	EFFECTS OF PROINFLAMMATORY CYTOKINES ON PERMEABILITY OF INTESTINAL EPITHELIAL MONOLAYERS IN VITRO	Benjamin Harvey	33	Gastro Urogenital
62	CHARACTERISATION OF MUSCARINIC RECEPTOR SUBTYPES IN THE HUMAN PROSTATE BY RADIOLIGAND BINDING	Donna Sellers	48	Gastro Urogenital
63	EXPRESSION, PURIFICATION AND CHARACTERISATION OF SOLUBLE HUMAN AND MOUSE CRISP-3, A PROTEIN HIGHLY EXPRESSED IN SEMINAL PLASMA	Marianna Volpert	62	Gastro Urogenital
64	IMMEDIATE EFFECTS OF DOXORUBICIN ON HUMAN UROTHELIAL CELL FUNCTION	Sung-Hyun Kang	67	Gastro Urogenital
65	CHARACTERISING T- CELL INTERACTIONS WITH INTESTINAL EPITHELIUM IN VITRO	Winston Reed	94	Gastro Urogenital
66	THE LAMINA PROPRIA IS RESPONSIBLE FOR THE GENERATION OF THE SPONTANEOUS CONTRACTILE ACTIVITY OF THE UROTHELIUM/LAMINA PROPRIA	Christian Moro	103	Gastro Urogenital
67	PACEMAKER CELLS AND CONTRACTILITY IN THE PROSTATE GLAND	Betty Exintaris	105	Gastro Urogenital
68	EFFECTS OF $\alpha$ 1A-ADRENOCEPTOR MODULATION, USING TAMSULOSIN, ON SPONTANEOUS ACTIVITY IN THE GUINEA PIG PROSTATE GLAND	Basu Chakrabarty	115	Gastro Urogenital
69	EFFECTS OF LIPOSTEROLIC EXTRACT OF SAW PALMETTO ON ISOLATED RAT PROSTATE	Thiam Chua	119	Gastro Urogenital
70	CALCIUM MOBILISATION DURING SPONTANEOUS ACTIVITY OF THE AGING GUINEA-PIG PROSTATE	Michelle Lam	121	Gastro Urogenital
71	INCREASED PHASIC CONTRACTIONS IN ISOLATED BLADDER STRIPS FROM AN OBESE RAT MODEL	Donna Sellers	134	Gastro Urogenital
72	CONTRACTION IN THE MOUSE PROSTATE GLAND DEVELOPS A PURINERGIC COMPONENT WITH AGE	Carl White	159	Gastro Urogenital
73	GENERATION OF $\alpha$ 1A-ADRENOCEPTOR & P2X1-PURINOCEPTOR DOUBLE KNOCKOUT MICE: EFFECT ON THE LOWER URINARY TRACT	Carl White	160	Gastro Urogenital
74	HEMOKININ-1 STIMULATES PRODUCTION OF PROINFLAMMATORY CYTOKINES AND CHEMOKINES IN HUMAN COLONIC MUCOSA THROUGH TACHYKININ NK1 AND NK2 RECEPTORS	Lu Liu	164	Gastro Urogenital
75	GASTRIC ACID SECRETION AND GASTROPROTECTION IN CHRONIC USERS OF NON-SELECTIVE NSAIDs	Doug McKittrick	171	Gastro Urogenital
76	THE ROLE OF TRPV1 IN P2X MEDIATED BLADDER AFFERENT SIGNALLING	Luke Grundy	183	Gastro Urogenital
77	ROLE OF NO/cGMP IN THE REGULATION OF SPONTANEOUS ACTIVITY IN THE GUINEA PIG PROSTATE GLAND	Anupa Dey	195	Gastro Urogenital
78	THE EFFECT OF THE CXCR2 CHEMOKINE RECEPTOR ON $\alpha$ 1A-ADRENOCEPTOR MEDIATED CONTRACTILITY IN THE RAT PROSTATE	Josephine Harsono	197	Gastro Urogenital

## ASCEPT POSTER PRESENTATIONS

PAVILION 1, LEVEL 1

### TUESDAY 6 DECEMBER

Poster Board Number	Abstract Title	Presenter	Abstract Number	Session Name
79	IMPROVING HETEROGENEOUS ION CHANNEL EXPRESSION IN MAMMALIAN CELLS	Helen Irving	199	Gastro Urogenital
80	IS CRELD1 AN INTERACTING PROTEIN WITH THE $\alpha$ 1A-ADRENOCEPTOR?	Linzi Lim	206	Gastro Urogenital
91	NITRIC OXIDE-MEDIATED HETEROLOGOUS REGULATION OF Gi-COUPLED RECEPTORS	Anna-Marie Babey	14	Neuropharmacology
92	RAT MODEL OF VARICELLA ZOSTER VIRUS (VZV) INDUCED NEUROPATHIC PAIN	VASKAR DAS	23	Neuropharmacology
93	ESTABLISHMENT AND CHARACTERIZATION OF AN AT3B PROSTATE CANCER CELL-INDUCED RAT MODEL OF BONE CANCER PAIN	Arjun Muralidharan	32	Neuropharmacology
94	SEX DIFFERENCES IN NEUROPATHIC PAIN	Lauren Nicotra	39	Neuropharmacology
95	COUNTER REGULATION OF ACUTE MORPHINE, OXYCODONE AND REMIFENTANIL ANALGESIA: A TLR4-MEDIATED PHENOMENON?	Jacob Thomas	61	Neuropharmacology
96	TYPE-1 INTERFERON SIGNALLING IS INVOLVED IN THE REGULATION OF NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE	Myles Minter	66	Neuropharmacology
97	EXTRASYNAPTIC $\delta$ -CONTAINING GABAA RECEPTORS AS A NOVEL TARGET FOR $\gamma$ -HYDROXYBUTYRIC ACID (GHB)	Mary Chebib	78	Neuropharmacology
98	TYPE I INTERFERON: DOES IT PLAY A ROLE IN PARKINSON'S DISEASE?	Bevan Main	79	Neuropharmacology
99	THE ROLE OF TLR2, TLR4, AND THEIR INTERACTION IN NALOXONE-PRECIPIATED OPIOID WITHDRAWAL	Liang Liu	83	Neuropharmacology
100	TYPE I INTERFERON SIGNALLING IS A POTENTIAL THERAPEUTIC TARGET FOLLOWING TRAUMATIC BRAIN INJURY	Ila Karve	84	Neuropharmacology
101	AT LEAST TWO DISTINCT BINDING SITES FOR MLA EXIST AT THE N-TERMINAL REGION OF RAT $\alpha$ 4 $\beta$ 2 NICOTINIC ACETYLCHOLINE RECEPTORS	Taima Qudah	85	Neuropharmacology
102	THE EFFECT OF NOVEL GABAZINE ANALOGUES ON GABA RECEPTORS	IZUMI YAMAMOTO	86	Neuropharmacology
103	ROLE OF SEX AND TOLL-LIKE RECEPTORS IN ALCOHOL-OPIOID DRUG INTERACTIONS	Emily Sun	92	Neuropharmacology
104	3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) – INDUCED HYPERTHERMIA: WHAT IS THE ROLE OF STRIATUM?	Intan Omar	117	Neuropharmacology
105	DOSE-DEPENDENT CONDITIONED PLACE PREFERENCE AND CONDITIONED PLACE AVERSION INDUCED BY MDMA ARE ABOLISHED BY DOPAMINE OR OXYTOCIN ANTAGONIST PRE-TREATMENT	Zak Millar	130	Neuropharmacology
106	IDENTIFICATION OF ANTI-INFLAMMATORY COMPOUNDS FROM CINNAMON	Gerald Muench	149	Neuropharmacology
107	TRPV4 PHOSPHORYLATION AT NOVEL SITES IN RESPONSE TO PAR2 ACTIVATION REGULATES STIMULUS RESPONSES	Nicholas Veldhuis	154	Neuropharmacology
108	INVESTIGATION INTO NOVEL REGULATORY AND SIGNALLING MECHANISMS ASSOCIATED WITH OREXIN RECEPTOR- $\beta$ -ARRESTIN COMPLEX FORMATION	Werner Jaeger	161	Neuropharmacology
109	CANNABINOID AND DEXAMPHETAMINE EFFECTS ON PREPULSE INHIBITION OF THE STARTLE REFLEX IN HUMANS AND RODENTS: RELATIONSHIP TO SCHIZOPHRENIA	Mathew Martin-Iverson	166	Neuropharmacology
110	CANNABINOID EFFECTS ON REFERENCE AND WORKING MEMORY FUNCTIONS IN MICE	Avdesh Avdesh	169	Neuropharmacology
111	INVESTIGATION OF THE PSYCHOTIC LIKE EFFECTS OF COMBINED NEONATAL MK-801 ADMINISTRATION AND ISOLATION REARING IN THE RAT	Daniel Malone	173	Neuropharmacology
117	A NEW DEVELOPMENT IN TEACHING: THE EBOOK 'PHARMACOLOGY IN ONE SEMESTER'	Sheila Doggrell	19	Education
118	A SUCCESSFUL STRATEGY FOR SUPPORTING NURSING STUDENTS GIVEN ADVANCED STANDING INTO PHARMACOLOGY AND BIOSCIENCE UNITS	Sheila Doggrell	20	Education
119	EVALUATION OF E-PHARMACOLOGY: AN ONLINE LEARNING RESOURCE FOR MEDICAL STUDENTS	Nami Nagar	125	Education
120	GROUP PRESENTATIONS AND PEER ASSESSMENTS – THE VIEWS OF THE STUDENTS	Suong Ngo	190	Education
121	CAN MULTIPLE CHOICE QUESTIONS ASSESS DEEPER LEVELS OF LEARNING – A STUDY EXPLORING MCQ AND THEIR ASSESSMENT OF THE USE AND APPLICATION OF KNOWLEDGE	Suong Ngo	191	Education
136	RNA APTAMER FOR CANCER STEM CELL-TARGETED THERAPY	Wei Duan	18	Drug Discovery
137	CXCL12-INDUCED CALCIUM RELEASE IN BREAST CANCER CELLS	Siti Yusrina Nadiyah Jamaludin	30	Drug Discovery
138	TWO-PORE CHANNELS IN BREAST CANCER CELL LINES	Aisyah H Jahidin	31	Drug Discovery
139	IS THE POTENTIAL FOR INTER-ETHNIC DIFFERENCES IN DRUG RESPONSE PROFILED DURING DRUG DEVELOPMENT?	Carol Lee	42	Drug Discovery
140	THE MEDICINAL POTENTIAL OF SCAEVOLA SPINESCENS: TOXICITY, ANTIBACTERIAL AND ANTIVIRAL ACTIVITIES	Ian Cock	52	Drug Discovery
141	PHARMACOGNOSY: DOCUMENTING NATURAL PRODUCTS AND TRADITIONAL MEDICINES TO ENHANCE DRUG DISCOVERY	Ian Cock	53	Drug Discovery
142	ANTIBACTERIAL ACTIVITY AND TOXICITY OF TERMINALIA FERDINANDIA (KAKADU PLUM) FRUIT EXTRACT	Shimony Mohanty	54	Drug Discovery
143	COLLOIDAL METALLIC SILVER (CMS) AS AN ANTISEPTIC: TWO OPPOSING VIEWPOINTS	Shimony Mohanty	55	Drug Discovery
144	P2Y RECEPTORS COUPLE TO HUMAN TRPA1 IN HEK293 CELLS	Liuqiong Gu	95	Drug Discovery
145	REMODELLING OF CALCIUM RELEASE CHANNELS IN BASAL BREAST CANCER CELLS UNDERGOING EGF-INDUCED EMT	Michelle Parsonage	219	Drug Discovery

## REGISTRATION DESK

On arrival delegates should make their way to the registration desk located on Level 2 of the PCEC where they will receive a name badge upon registration. The badge will be your official pass and must be clearly visible at all times to obtain entry to all sessions. If you have any queries regarding registration, please visit the **registration desk**. The desk will open on **Sunday 4 December 2011** from **1230 onwards** and will operate for the duration of the Joint Meeting between the following hours:

Sunday December 4	1230 onwards
Monday December 5	0730 – 1830
Tuesday December 6	0730 – 1830
Wednesday December 7	0730 – 1230

## PROGRAM

Delegates and speakers will receive a hard copy of Joint Meeting program and a copy of the proceedings published on CD-ROM. Should you wish to view abstracts during the Joint Meeting please visit the Speakers Preparation Room (Meeting Room 12) where IT facilities will be provided.

## SPEAKERS PREPARATION ROOM

Speakers will need to register at the registration desk when they first arrive at the Joint Meeting to collect their name badge and other related materials. From there you will be directed to the Speaker Preparation Room located in Meeting Room 12, Level 2 where you must check in with the audio visual technicians.

All speakers are asked to load/check their presentation **no later than one hour prior** to their session commencing to ensure the presentation is checked and tested. Roaming AV technicians will be onsite to assist with any troubleshooting during sessions. Presentations must be provided on a USB (memory stick), with the file in a PowerPoint PC format. Please note that there will be NO time to swap computers over between presentations.

## POSTER PRESENTATIONS

Posters are required to be put up in Pavilion 1, Level 1 **no later than 8.00am Monday morning 5 December**, and they will stay up until the close of the Joint Meeting on Wednesday 7 December.

Presenters should be prepared to provide a two minute synopsis of their posters when requested by judging panels. Presentation times will be:

- Monday 5 December, 8.00am to 9.00am – ASCEPT breakfast poster session
- Tuesday 6 December, 8.00am to 9.00am – ASCEPT breakfast poster session
- Wednesday 7 December, 12.30pm to 2.00pm – ASCEPT student poster prize session

Student poster presenters are eligible for the ASCEPT Neville Percy, ASCEPT Robert Whelan or the ASCEPT Integrative Pharmacology/ Toxicology Poster Prizes.

## INTERNET CONNECTIVITY

The PCEC is a Wi-Fi Zone wireless internet location. This service is complimentary to delegates and visitors to the PCEC and provides wireless connection anywhere in and around the venue. Speed for the complimentary internet is 256k, higher speeds are available by purchasing online through the PCEC wireless internet online portal once at PCEC. **Wireless Internet Login details for the Joint Meeting are Username: Joint Meeting, Password: wireless.**

## EXHIBITORS & SPONSORS

The exhibition area will be co-located with the Poster Presentation area in Pavilion 1, Level 1. All catering will be centred around the exhibition booths to allow delegates to network with exhibitors throughout the Joint Meeting.

### FOR ALL OTHER ENQUIRIES

Please contact the Joint Meeting Organiser, CLEMS  
email: [ascept@clems.com.au](mailto:ascept@clems.com.au) or Tel: +613 9416 3833.

## SOCIAL PROGRAM

**Welcome Reception** – Sunday 4 December 2011  
1830 – 2030 (Pavilion 1, Level 1, PCEC)

**Joint Meeting Dinner** – Wednesday 7 December 2011  
7.00pm pre-dinner drinks and canapés  
7.30pm to 11.30pm dinner (Bellevue Ballroom 2, Level 3, PCEC)

The Joint Meeting Dinner will be one of the memorable highlights of the 2011 Joint Scientific Meeting program. Guests will enjoy pre-dinner drinks and a three-course dinner and entertainment throughout the evening.

## GENERAL INFORMATION

**Mobile phones, pagers:** In the interests of courtesy to speakers and other delegates, please switch off these devices during sessions or switch them to 'vibrate'.

**Dress code:** Dress for the Joint Meeting sessions, welcome reception and Joint Meeting dinner is smart casual.

**Daily notices/messages:** All information on changes to the program and other items of interests to participants will be posted daily on a notice board at the Registration Desk. Delegates should check the noticeboard regularly for incoming messages and faxes.

**Disclaimer:** The organising committee reserves the right to make program changes if deemed necessary.

**No Liability:** In the event of any disruption or event leading to losses or added expense being incurred in respect of the Joint Meeting, there shall be no liability attached to the Joint Meeting Hosts or the Joint Meeting Organisers. The Joint Meeting Hosts and the Joint Meeting Organisers cannot take any responsibility for any delegate failing to arrange their own insurance.

**Privacy:** Information collected in respect of proposed participation in any aspect of the Joint Meeting will be only used for the purposes of planning and conduct of the Joint Meeting and may also be provided to the organising body, or to organisers of future events. It is also usual to produce a 'Delegate List' of attendees at the Joint Meeting and to include the individual's details in such a list (name, institution, state and country). Only individuals who elected to include their details on the 'Delegate List' at the time of registering will be included. It is the intention to provide a Delegate List to delegates and sponsors.

## PARKING

The City of Perth Convention Centre Car Park is located directly under the PCEC which operates 24 hours, 7 days a week. This car park is accessible via Mill Street, Mounts Bay Road and the Riverside Drive off ramp of the Mitchell Freeway. Payment for parking can be made by cash, credit card or with the City of Perth Parking Card. Direct access to the PCEC from the City of Perth Convention Centre Car Park is available during opening hours via our central foyer lift and two staircases.

## PUBLIC TRANSPORT

**Taxi:** Perth Convention and Exhibition Centre is a designated Cab Spot location. A taxi phone is located at our Plaza Entry doors on Level 1. Our Cab Spot number is 1088. Alternatively, to book a taxi, please contact **Swan Taxis** 13 13 30 or **Black and White Taxis** 13 10 08.

**Buses:** Esplanade Busport is located adjacent to Perth Convention and Exhibition Centre. Many bus services depart and arrive at the Esplanade Busport including the free CBD 'Blue CAT' service. Perth's other major busport is the Wellington Street Bus Station, located along Wellington Street next to the Perth Central train station.


**Train:** Esplanade train station is located at the doorstep of the Centre and services the Mandurah and Joondalup Railway Line. Other train stations within close proximity of the centre include Perth Underground station (Mandurah and Joondalup Railway Line) located on the corner of William Street and Murray Street Mall. An underground walkway connects the Perth Central station to the Perth Underground station.

**Cycling:** Bicycle parking can be found off William Street near the Convention and Exhibition Centre.

# PAVILION 1, LEVEL 1


## POSTER PRESENTATIONS/EXHIBITION/ALL CATERING

ASCEPT-AuPS-HBPRCA  
JOINT SCIENTIFIC MEETING 2011



# MEETING ROOMS, LEVEL 2

## REGISTRATION DESK/PLENARIES/CONCURRENT SESSIONS



### MEETING ORGANISER CLEMS

Suite 5, 250 Gore Street, Fitzroy 3065  
T +61 3 9416 3833  
F +61 3 9416 0636  
E [ascept@clems.com.au](mailto:ascept@clems.com.au)

